Final exam
Definition and Overview of Space Occupying Lesions
Intracranial Space-Occupying Lesions (ISOL): These are defined as tumors, fluids, and abscesses present within the cranium or skull.
Pathological Mechanism: These lesions exert pressure on adjacent brain tissue, causing damage. While they arise from various causes, they share the common feature of expanding the volume of intracranial contents.
Mass Effect: A mass effect is the result of the physical lesion itself combined with the surrounding edema.
Intracranial Pressure (ICP)
Definition: ICP is the pressure exerted by fluids, such as cerebrospinal fluid (CSF), inside the skull and on the brain tissue.
Measurement:
ICP is measured in millimeters of mercury ().
Normal resting ICP for a supine adult is .
Severely high ICP can lead to brain herniation.
Monitoring Standard: The ventriculostomy is considered the gold standard for monitoring ICP, though it carries a risk of infection.
Classification of Space Occupying Lesions
Congenital: Includes dermoid, epidermoid, and teratoma.
Traumatic: Includes subdural and extradural (epidural) hematomas.
Inflammatory: Includes abscesses, tuberculomas, syphilitic gumma, and fungal granulomas.
Parasitic: Includes cysticercosis, hydatid cysts, amebic abscesses, and Schistosoma japonicum.
Neoplasms (Tumors): Primary, metastatic, and non-neoplastic cysts.
Vascular: Aneurysms, Arteriovenous Malformations (AVMs), and stroke.
Major Mechanisms of Brain Dysfunction
Localized space-occupying lesions exert effects through three principal mechanisms:
Direct Effect: destruction or functional impairment of structures adjacent to the lesion.
Secondary Effect of Raised ICP:
Results from the lesion, accompanying edema, or obstruction of CSF outflow.
Obstruction typically occurs at the level of the 4th ventricle or the aqueduct of Sylvius, producing hydrocephalus.
The degree of ICP increase is largely dependent on the rate of growth of the lesion.
Provocation of Seizures:
Partial or generalized seizures are common, particularly in patients with cerebral abscesses and neoplasms.
New onset focal sensory or motor seizures are common presenting features of both primary and secondary CNS tumors in adults.
Cerebral Abscesses
Definition: A localized collection of necrotic tissue or pus developing from focal encephalitis (brain tissue infection).
Mechanisms of Spread:
Direct Spread: Infection moves from the paranasal sinuses or middle ear.
Septic Sinus Thrombosis: Infection spreads from the paranasal sinuses or middle ear via the sigmoid sinus.
Haematogenous Spread: Infection from a distant focus embolizes and seeds in the brain.
Typical Morphology:
Central necrotic fluid.
Fibrous capsule.
Zone of reactive gliosis.
Edema surrounding the fibrotic capsule.
Clinical Presentation:
Neurologic: Symptoms of raised ICP (nausea, vomiting), focal neurologic deficits (hemiparesis), and seizures.
Systemic Toxicity: Fever and malaise.
Primary Source Symptoms: Evidence of otitis or sinusitis.
Treatment Protocols:
Infection Control: Antibiotics and possibly hyperbaric oxygen therapy.
ICP Management: Draining the abscess, shunts for hydrocephalus, mannitol, or corticosteroids.
Seizure Control: Anti-epileptic medications.
Surgical Options: Burr hole and aspiration or excision via craniotomy for recurrent abscesses. Pus should be sent for Culture and Sensitivity (C&S).
Brain Tumors: Classification and Pathogenesis
Primary Tumors: Originate from cells within the CNS. They generally do not spread outside the CNS, although medulloblastomas and ependymomas can spread via CSF pathways.
Secondary (Metastatic) Tumors: Originate outside the CNS and seed to the brain via the lymphatic system or blood vessels. These are considered malignant due to their systemic spread.
Common Sources: Lung, Kidney, Breast, Gastrointestinal, and Prostate.
Malignancy Types based on Cell Origin:
Glial cells (Gliomas).
Neurons.
Meningeal arachnoid cells (Meningiomas).
Lymphoreticular cells.
Specific Primary Tumor Profiles:
Gliomas: Present with seizures, language difficulty, headaches, behavioral changes, and hemiparesis.
Meningiomas: Often slow-growing, occurring in middle age; symptoms include headache and seizures.
Pituitary Adenoma: Causes headache, visual effects, and endocrine disruption (e.g., Gigantism, Acromegaly, Cushing's syndrome, Hypopituitarism).
Schwannomas: Present with hearing problems, vertigo, headache, and facial weakness/numbness.
Pineal Region Tumors: Symptoms include headache, hydrocephalus, and Parinaud's Syndrome.
Pathophysiology of Brain Neoplasms
Etiology: Mutagen exposure (radiation, carcinogens), DNA replication errors, acquired cell mutations (uncontrolled division), or inherited diseases (neurofibromatosis, tuberous sclerosis).
Vascular Effects: Tumors produce Vascular Endothelial Growth Factor (VEGF), leading to angiogenesis. These new vessels are friable, leading to brain hemorrhage. Disrupted blood-brain barriers allow increased serum leakage, causes edema, and increases penetration of toxins/drugs.
Tissue Effects: Tumors invade, infiltrate, or replace normal brain parenchyma. They may outgrow their blood supply, causing ischemia and necrosis.
Mass Effect:
Frontal Lobe Damage: Personality changes.
Cerebellar Damage: Ataxia.
Occipital Lobe Damage: Visual deficits.
Ventricular Obstruction: Obstructive hydrocephalus.
Brain Herniation: Tissue is pushed down beyond the tentorium cerebelli, squeezing the brain stem.
Clinical Presentation by Anatomical Region
Frontal Lobe: Inappropriate behavior, inattentiveness, inability to concentrate, emotional lability, impaired recent memory, difficulty with abstraction, irritability, depression, poor judgment, and childish behavior.
Parietal Lobe: Decreased tactile sensitivity, loss of right-left discrimination, construction apraxia, and seizure activity.
Temporal Lobe: Auditory, visual, or olfactory hallucinations; receptive aphasia.
Occipital Lobe: Visual disturbances and visual hallucinations.
Cerebellum: Ataxia and incoordination.
Brainstem: Dysphagia, vomiting, and motor/sensory tract deficits.
Midbrain: Cerebellar symptoms, deafness, and decreased light reflex.
Ventricular: Headache, vomiting, and signs of increased ICP.
Diagnosis and Medical Management
Diagnostics: Physical exam, CT brain scan, MRI brain, MR angiography, Biopsy, and Lab studies (CBC, ESR, LFTs, tumor markers).
Medical Management:
Dexamethasone (Decadron): Reduces cerebral edema.
Phenytoin: Prevents or treats seizure activity.
Mannitol: Osmotic diuretic to lower ICP.
Antibiotics: For inflammatory lesions.
Surgical Management:
Craniotomy: Temporal removal of a bone flap for brain surgery (later returned).
Craniectomy: Surgical removal of a bone flap (not immediately replaced) to relieve pressure.
Transsphenoidal Surgery: Low-cost, minimally invasive approach for pituitary tumors.
Other: Gamma knife, laser surgery, interventional radiotherapy, and shunts for hydrocephalus.
Intracranial Hematomas
Extradural (Epidural) Hematoma:
Located between the dura and the skull.
Commonly involves the middle meningeal artery in the temporal fossa.
Clinical Features: Progressive deterioration of LOC, lucid intervals, and Hutchinson’s pupillary reaction.
Subdural Hematoma:
Located between the dura and the arachnoid.
Caused by bleeding from superficial veins or venous sinuses (often associated with anticoagulant treatment).
Acute: Similar presentation to extradural.
Chronic: Presents as dementia, altered behaviors, or focal neurologic deficits.
Vascular Space Occupying Lesions and Infarction
Brain Aneurysm: A bulge/ballooning in a blood vessel.
Saccular (Berry): Round, blood-filled sac hanging from an artery.
Fusiform: Bulging on all sides of the artery.
Mycotic: Caused by infection weakening the arterial wall.
Rupture: Causes subarachnoid hemorrhage (hemorrhagic stroke).
Arteriovenous Malformation (AVM): Congenital or acquired shunt between arteries and veins. Lack of regulation can cause aneurysmal dilation of draining veins. No space-occupying effect exists unless hemorrhagic or thrombotic complications occur.
Infarction: Tissue death resulting from lack of oxygen supply () or bleeding ().
Stroke Types:
Ischemic: A clot blocks blood flow.
Hemorrhagic: Bleeding occurs inside or around brain tissue.
# Fundamentals of Diaphragmatic Function
The diaphragm is the primary muscle of inspiration, accounting for of ventilation.
It acts as a musculo-fibrous membrane that separates the thoracic and abdominal cavities.
Dysfunction of the diaphragm leads to significant adverse clinical consequences, including:
Respiratory symptoms.
Exercise intolerance.
Sleep disturbances.
In severe cases, a negative impact on overall survival.
Diagnosis is often complicated because the condition is relatively rare, clinical manifestations are subtle, and obtaining a physiologically-confirmed diagnosis is difficult.
Anatomical and Histological Considerations
The diaphragm consists of two main parts: a non-contractile central fibrous portion and a peripheral muscular section.
The muscular section is divided into three distinct groups:
Sternal muscular group.
Costal muscular group.
Lumbar muscular group.
Histologically, the muscular component contains approximately equal proportions of two fiber types:
Type I fibers: Slow, fatigue-resistant fibers.
Type II fibers: Fast fibers.
This balanced composition allows the diaphragm to support the low-intensity, perpetual breathing cycle as well as rapid, strenuous activities such as talking, singing, sneezing, and situations requiring acutely increased ventilation.
The diaphragm is categorized into two functional zones:
Zone of Apposition: Characterized by a high content of muscular tissue. It is mostly rectilinear and runs parallel to the ribcage.
Dome Area: Characterized by a low content of muscular tissue. It is dome-shaped and runs perpendicular to the ribcage.
Innervation and Neurological Pathways
Afferent neurological inputs originate mainly from the phrenic nerves, derived from the third, fourth, and fifth cervical nerves (, , and ) bilaterally.
Progression of the phrenic nerves:
At the neck level, both nerves descend anteriorly to the scalene muscles.
They enter the thorax between the subclavian arteries and veins.
The right phrenic nerve runs caudally anterior to the brachiocephalic trunk, borders the right atrium, and enters the abdominal cavity via the caval hiatus.
The left phrenic nerve runs caudally along the left ventricle and enters the diaphragm independently.
Once on the abdominal side, the phrenic nerves divide into four branches to allow full innervation of the muscle:
Anterolateral branch.
Posterolateral branch.
Crural branch.
Sternal branch.
Other anatomical landmarks include the Inferior Vena Cava (IVC) hiatus and the Esophageal Hiatus (EH).
Mechanics of Diaphragmatic Movement
Diaphragm thickness is variable, being thicker in the dome portion and tapering toward the sides.
Under normal conditions, the diaphragm functions like a piston within the chest:
The dome descends into the thoracic cavity.
This movement displaces abdominal contents caudally (downward) and elevates the lower thorax.
The resulting negative intrathoracic pressure generates an inflow of air from the mouth to the lung, creating tidal volume ().
Etiology of Unilateral Diaphragmatic Paralysis
Unilateral paralysis is often first suspected when an abnormally elevated hemidiaphragm is found on a chest radiograph (CXR).
Radiographic definition of elevation:
A right hemidiaphragm sitting > 2\,cm higher than the left.
A left hemidiaphragm sitting equal to or higher than the right.
Note: This finding is common and not a decisive indicator of paralysis on its own.
Common traumatic causes:
Coronary Artery Bypass Grafting (CABG) surgery: Phrenic nerve lesions are frequently associated with this procedure.
Harvesting of the Internal Mammary Artery (IMA): High risk due to the close anatomical relationship between the phrenic nerve and the IMA.
Use of topical ice slush for cardiac cooling: Can induce traumatic demyelinating injury to the phrenic nerve due to cold temperatures.
Compressive or infiltrative processes:
Mediastinal or pulmonary malignancy.
Pathological lymph nodes.
Goiter.
Cervical arthrosis and spondylosis.
Inflammatory and infectious diseases:
Shingles.
Parsonage-Turner Syndrome (neuralgic amyotrophy): Presents with unilateral phrenic palsy, typically resolving over one to three years.
Mononeuritis.
Chronic inflammatory demyelinating polyneuropathy.
Post-viral conditions.
Additional causes:
Neck surgery, or lung/liver/heart transplantation.
Chiropractic manipulation.
Central venous cannulation or nervous blockade.
Central neurological diseases such as stroke, multiple sclerosis, or rhizotomy.
Idiopathic (unknown) causes.
Etiology of Bilateral Diaphragmatic Weakness
Bilateral weakness is most commonly encountered in generalized degenerative muscular or neurological disorders.
Systemic and specific medical causes:
Systemic Lupus Erythematosus (SLE): Leads to "Shrinking Lung Syndrome," a rare complication marked by a progressive decline in lung volumes.
Dermatopolymyositis.
Diseases of the neuromuscular junction.
Hypothyroidism.
Malnutrition.
Lung Hyperinflation and COPD:
Chronic hyperinflation (as seen in COPD) reduces the pressure-generating capacity of the diaphragm.
Hyperinflation shortens muscle fibers, placing the diaphragm at a mechanical disadvantage by forcing it to contract on the steep part of its length-tension curve.
Diaphragmatic Dysfunction in the Intensive Care Unit (ICU)
Acquired diaphragm dysfunction in the ICU impacts weaning outcomes, duration of mechanical ventilation (MV), survival, and long-term prognosis.
Mechanical Ventilation (MV) is a primary contributor:
MV can induce significant diaphragm muscle fiber atrophy detectable within the first .
This phenomenon is sometimes referred to as diaphragmatic myotrauma.
Mechanisms of MV-induced weakness:
Increased oxidative stress load.
Downregulation of protein synthesis.
Activation of proteolytic pathways.
Weakness may be exacerbated by the use of neuromuscular blocking agents.
Clinical Presentation and Physical Examination
Unilateral diaphragm weakness may be asymptomatic but can cause symptoms in patients with obesity or underlying cardiorespiratory disease:
Orthopnea and dyspnea when bending forward.
Dyspnea on exertion.
Coughing and chest pain.
Symptoms of sleep-disordered breathing.
Bilateral diaphragm weakness symptoms:
Severe dyspnea when supine (lying flat) and during exertion.
High likelihood of sleep-disordered breathing features.
Physical examination findings:
Dullness to percussion.
Decreased diaphragmatic excursion.
Tachypnea.
Use of accessory muscles of respiration.
Paradoxical inward movement of the abdomen during inspiration.
Diagnostic Investigations and Measurements
Maximal Inspiratory Pressures (MIP):
Measures inspiratory pressure at the mouth during maximal effort against a closed mouthpiece.
Simple and well-tolerated but effort-dependent.
Represents all inspiratory muscles, not just the diaphragm.
A MIP < -80\,cmH_2O generally excludes significant muscle weakness.
Unilateral paralysis typically decreases MIP to ~ of predicted values; bilateral paralysis reduces it to < 30\% of predicted values.
Transdiaphragmatic Pressure ():
Measured using balloon catheters in the lower esophagus (measuring pleural pressure, ) and the stomach (measuring intra-abdominal pressure, ).
Calculated as the difference between these two measurements ().
Measurements can be taken during tidal breathing, maximum inspiratory effort (), or the sniff maneuver ().
Phrenic Nerve Stimulation and Imaging
Phrenic Nerve Stimulation is the gold standard for quantifying mechanical function.
It measures negative pressure generated by diaphragm contraction in response to stimulation.
Pressure is monitored via "twitch transdiaphragmatic pressure" or twitch mouth/tracheal pressures in intubated patients.
Methods include transcutaneous electrical stimulation at the neck (can be uncomfortable) or magnetic stimulation (painless, reproducible, applied at the cervical spine or neck).
Fluoroscopy (Sniff Test):
Dynamic evaluation of movement.
Paradoxical upward motion of the abnormal hemidiaphragm during a short, sharp voluntary sniff confirms diagnosis.
A normal subject generates a of ~, while a weak patient may generate only .
Pulmonary Function Testing and Ultrasonography
Spirometry in the Supine Position:
Unilateral weakness: Mild decrease in Vital Capacity (VC) to ~ predicted, with a further drop when supine. Total Lung Capacity (TLC) and Functional Residual Capacity (FRC) are usually preserved.
Bilateral weakness: VC drops to ~ predicted, with a further decrease when supine. TLC is reduced; Residual Volume (RV) may be elevated.
The magnitude of VC fall in the supine position correlates with transdiaphragmatic pressure.
Ultrasonography:
Static measurement: Diaphragm thickness ().
Dynamic evaluation: Inspiratory diaphragm thickening fraction () and excursion ().
Assesses muscle trophic status (is it in good shape?), contractility, and movement amplitude.
Sleep and Exercise Studies
Sleep Studies:
Patients with unilateral weakness may exhibit central hypopnea due to respiratory pump weakness.
Polysomnography should be considered early for patients with severe weakness.
Cardiopulmonary Exercise Testing (CPET):
Evaluates exercise performance to demonstrate negative repercussions in asymptomatic patients.
Quantifies respiratory impairment and monitors clinical evolution.
Prognosis
Highly variable based on etiology.
Unilateral disease: Excellent vital prognosis. Spontaneous recovery is more frequent in post-operative phrenic injury compared to idiopathic disease.
Neuralgic amyotrophy/Idiopathic disease: Partial recovery may occur but can take years.
Therapeutic Management and Interventions
General Management:
Optimal medical management of concurrent conditions.
Inspiratory Muscle Training (IMT): Uses resistive or threshold loading. Benefits patients with COPD, spinal cord injury, or post-CABG phrenic damage by increasing maximal inspiratory pressures.
Ventilatory Support:
Continuous Positive Airway Pressure (CPAP) for sleep-disordered breathing.
Non-invasive Bi-level Airway Pressure (BiPAP) or Non-Invasive Positive Pressure Ventilation (NPPV/NIV) for nocturnal hypoventilation or severe weakness.
Surgical Plication (Unilateral):
Considered if weakness persists for months in symptomatic patients.
The weak hemidiaphragm is immobilized with surgical folds to reduce paradoxical movement.
Improves ventilation/perfusion anomalies and reduces the workload on the functional side.
Phrenic Nerve Pacing (Bilateral):
Indicated for highly selected ventilator-dependent patients (e.g., upper-level spinal cord injury patients after at least three months).
Requires intact phrenic nerve function, adequate cognitive status, and absence of severe lung/chest wall disease.
Electrodes are implanted at the thoracic level or on the abdominal aspect of the diaphragm to recover physiological contraction and reduce ventilatory support.
ICU Strategies:
Preference for partially supported ventilatory modes over controlled ventilation to promote continuous diaphragmatic activity and prevent atrophy.
Systemic Inflammatory Response Syndrome (SIRS)
SIRS is an inflammatory clinical response of the whole body that occurs without a proven source of infection.
The condition leads to disorders of microcirculation and organ perfusion, which eventually results in secondary organ dysfunction.
Triggering causes are non-specific and include:
Ischemia.
Inflammation.
Trauma.
Infection.
A combination of the above factors.
SIRS Clinical Definition
SIRS is defined by the presence of 2 or more of the following variables:
Temperature: > or < .
Heart Rate (HR): > .
Respiratory Rate (RR): > or PaCO_2 < 32\,\text{mmHg}.
White Blood Cell (WBC) Count: Abnormal count > or < .
Sepsis and Its Progression
Sepsis: Defined as SIRS with a confirmed source of infection through blood or tissue cultures. It can also be characterized as SIRS with a presumed or confirmed infectious process.
Severe Sepsis: Sepsis associated with at least one sign of organ failure. Systems affected may include:
Cardiovascular (refractory hypotension).
Renal.
Respiratory.
Hepatic.
Hematologic.
Central Nervous System (CNS).
Metabolic acidosis.
Mechanisms of Sepsis:
Chemicals released into the bloodstream to fight infection trigger inflammatory responses throughout the body.
These responses can damage vital organs (lungs, heart, liver, kidneys).
Manifestations include clots and leaky vessels.
Leaking vessels impair the body's ability to pump blood containing vital nutrients to tissues and organs.
Decreased blood flow results in poor nutrient exchange and tissue swelling.
Multiple Organ Dysfunction Syndrome (MODS): Definition and Classification
MODS is defined as the presence of altered organ function in a client who is acutely ill, such that homeostasis cannot be maintained without intervention.
It requires medical intervention to support continued organ function.
MODS is considered present when 2 or more organs fail.
MODS results directly from SIRS.
Classification: Primary and Secondary MODS
Primary MODS:
Immediate dysfunction or failure occurring simultaneously in 2 or more organs due to a primary disease.
A direct insult initially causes a localized inflammatory response that may or may not progress to SIRS.
Example: Primary pulmonary injury such as aspiration.
Only a small percentage of clients develop primary MODS.
Secondary MODS:
Delayed consequence of widespread systemic inflammation.
Develops after a variety of insults and results in the dysfunction of organs not involved in the primary insult.
The client enters a hypermetabolic state lasting to days.
During this period, the body catabolizes muscle and fat for energy, causing changes in metabolic processes.
Occurs with conditions such as Acute Respiratory Distress Syndrome (ARDS) and septic shock.
Risk Factors and Etiology of MODSRisk Factors
Elderly patients.
Patients with chronic illness and malnutrition.
Severe trauma or multiple injuries.
Massive blood loss.
Hypovolemic shock (associated with ruptured aneurysm, acute pancreatitis, sepsis, burns, or surgical complications).
Chronic inflammatory responses (e.g., sepsis).
Surgery and massive blood transfusions.
Etiology
Infection (SIRS/Sepsis).
Pancreatitis.
Aspiration syndromes.
Injury (accidents, burns, surgery).
Ischemia-reperfusion injury.
Poisoning toxicity.
Hypoperfusion and hypermetabolism.
Extracorporeal Membrane Oxygenation (ECMO).
Multiple blood transfusions.
Autoimmune disease.
Heat-induced illness.
Eclampsia.
Pathophysiology of MODSInitial Sequence
Local injury occurs from trauma, infection, or lack of perfusion.
Disturbed inflammatory immune response.
Bacteria enter wounds and release toxins.
Systemic mediators of inflammation are activated.
Chemical mediators or endotoxins target and damage the endothelium.
Progression to Organ Damage
Unchecked inflammatory responses produce damage to the respiratory, cardiovascular, nervous, and renal systems.
Tissues are damaged by:
Altered perfusion.
Disturbed oxygen supply or demand.
Metabolic dysfunction.
Coagulopathy.
The progression follows the path: SIRS + Infection Sepsis Severe Sepsis MODS.
Pathophysiology and Clinical Manifestations by SystemRespiratory System
Pathophysiology: Inflammatory mediators affect pulmonary vasculature and damage the endothelium. This increases capillary permeability, moving proteinaceous fluid into interstitial spaces. Alveoli collapse, increasing shunting and worsening ventilation-perfusion () mismatch, leading to ARDS.
Clinical Manifestations:
Dyspnea and increased respiratory rate.
Bilateral fluffy infiltrates on chest X-ray.
Pulmonary hypertension.
Decreased compliance and decrease in surfactant.
Alveolar edema and hypoxemia.
Cardiovascular System
Pathophysiology: Massive vasodilation and myocardial depression occur. Systemic Vascular Resistance (SVR) and blood pressure decrease. Capillary permeability shifts albumin and fluid out of the vascular space, diminishing venous return and preload.
Initial Response: Myocardial depression, decreased SVR, decreased venous capacitance, and increased CO and HR to compensate for hypotension.
Late Response: Ventricular dilatation, decreased diastolic compliance, decreased contractile function, and inability to maintain BP without vasopressors.
Clinical Manifestations: Hypotension, vasodilation, increased HR, decreased stroke volume, and decreased Mean Arterial Pressure (MAP).
Nervous System
Pathophysiology: Mediated by impaired cerebral perfusion, metabolic alterations, the direct effect of inflammatory mediators, and the effects of sedatives/analgesics.
Clinical Manifestations: Confusion, agitation, disorientation, lethargy, coma, seizures, and hepatic encephalopathy.
Renal System
Pathophysiology: Acute Renal Failure (ARF) caused by hypoperfusion, mediator effects, or nephrotoxic drugs. Decreased perfusion activates the Sympathetic Nervous System (SNS) and the Renin-Angiotensin System, causing systemic vasoconstriction and aldosterone-mediated sodium/water reabsorption.
Clinical Manifestations: Oliguria (decreased urine output), fluid and electrolyte imbalances, and increased creatinine.
Gastrointestinal System
Pathophysiology: Hypoperfusion leads to decreased integrity of the gut lining and mucosal ischemia. This allows translocation of normal GI bacteria into systemic circulation, leading to further SIRS. Decreased peristalsis occurs, and bacteria may colonize the oropharynx, risking aspiration and lung inflammation.
Clinical Manifestations: GI bleeding, mucosal ulceration, and paralytic ileus.
Metabolic and Endocrine Systems
Pathophysiology: Hypermetabolic response. Glycogenolysis converts glycogen to glucose. Once depleted, gluconeogenesis converts amino acids to glucose, depleting protein stores. Fatty acids are mobilized. Catecholamines and glucocorticoids cause hyperglycemia and insulin resistance.
Clinical Manifestations: Hyperglycemia, increased Antidiuretic Hormone (ADH) and Adrenocorticotropic Hormone (ACTH), and muscle loss due to a catabolic state.
Hematologic and Immune Systems
Hematologic Pathophysiology: Failure of the coagulation system leads to Disseminated Intravascular Coagulopathy (DIC), featuring simultaneous microvascular clotting and bleeding due to depletion of clotting factors and platelets.
Hematologic Manifestations: Increased bleeding time, increased PT, increased APTT, decreased platelet count, anemia, leucocytosis, or leukopenia.
Immune Response: Nosocomial infections (e.g., Staphylococci, Enterococci, Candida, Pseudomonas) are common due to impaired immunity.
Diagnosis and the MODS Scoring SystemDiagnostic Considerations
History: Underlying diseases, hypotension, oliguria/anuria, tachypnea, and immunocompromised status.
Physical Exam: Must include rectal, genital, and pelvic examinations to look for abscesses, Pelvic Inflammatory Disease (PID), or prostatitis.
The Multiple Organ Dysfunction Score (MODS)
The score ranges from to for each system based on specific parameters:
Respiratory ():
0: > 300
4: < 75
Renal (Serum Creatinine in ):
0: < 100
4: > 500
Hepatic (Serum Bilirubin in ):
4: > 240
Cardiovascular (Pressure Adjusted Heart Rate - PAR): Calculated as HR (CVP / MAP).
4: > 30
Hematologic (Platelet count in ):
0: > 120
Neurologic (Glasgow Coma Scale):
Relationship Between MODS Score and Mortality
Score of : mortality.
Score of : mortality.
Score of : mortality.
Score of : mortality.
Score > : mortality.
Management and Treatment StrategiesOverview of Treatment
Control the infection.
Maintain tissue oxygenation.
Provide nutritional and metabolic support.
Apply organ-specific supportive treatment.
Stepwise Approach (ABCDEFGHIJKL)
A - Airway: Ensure protection; intubate if required.
B - Breathing: Assess oxygenation/ventilation; administer oxygen or Mechanical Ventilation (MV).
C - Circulation: Fluid resuscitation to restore volume; use invasive monitoring and vasopressors if needed.
D - Diagnosis/Detective Work: History, physical exam, and identification of source.
E - Empiric Therapy: Initiate empiric antibiotics.
F - Find and Control Infection: Lab investigations and surgical removal of necrotic tissue.
G - Gut: Feed enterally to prevent villus atrophy and bacterial translocation.
H - Hemodynamics: Assess fluid resuscitation adequacy and end-organ perfusion.
I - Iatrogenic: Avoid hospital-acquired injuries (bed sores, line infections); manage analgesia, sedation, and blood sugar.
J - Justify Therapeutic Plan and Reassess: Check for second hits or superinfections.
KL - Keep Looking: Ensure the source is controlled; look for secondary infection sources.
Specific Interventions
Maintain Tissue Perfusion: Decrease oxygen demand (MV, analgesia, paralysis/rest) and optimize delivery (maintain Hb levels, appropriate , enhance CO by increasing preload/contractility or reducing afterload).
Control Mediators: Use monoclonal antibodies for endotoxins, Interleukin-1, and tumor necrosis factors. Maintain a positive nitrogen balance.
Prognosis and Recovery
If MODS is not reversed by day , the client will usually die.
Death typically occurs between days and after the precipitating event.
MODS is the leading cause of death in the ICU, with mortality rates between and .
For survivors:
Average ICU stay is days.
Rehab and recovery of lost muscle mass usually takes approximately months.
Development Models and Clinical StagesClinical Application Case (38-year-old male)
Scenario: Abdominal injuries/liver laceration from Motor Vehicle Collision (MVC). Status post-laparotomy and splenectomy.
Day 2: Stable, nasal prong O2 for of , HR , no bowel sounds, NG drainage.
Days 6-7: Worsening condition; requiring O2 for of , fever , high WBC. Creatinine/BUN climbing (ARF), impaired hepatic function (bilirubin, AST, ALT), requiring vasoactive drugs.
Summary of Clinical Stages
Stage 1: Increased volume requirements, mild respiratory alkalosis, oliguria, hyperglycemia.
Stage 2: Tachypnea, hypocapnia, hypoxemia, moderate liver dysfunction, hematologic abnormalities.
Stage 3: Shock with azotemia, acid-base disturbances, significant coagulation abnormalities.
Stage 4: Vasopressor dependent, oliguric/anuric, ischemic colitis, lactic acidosis.
Developmental Models
One-hit Model: Massive response to initial injury/shock/hypoperfusion that overwhelms metabolic reserves.
Two-hit Model: Initial resuscitation leads to mild/moderate inflammation ("primed" state). A subsequent "second hit" (e.g., surgery, infection) triggers dysfunctional hyperinflammation and MODS. This model emphasizes a "vulnerable window" (e.g., significant neutrophilia at hours post-injury).
Peripheral Vascular Disease (PVD): Definition and Etiology
Peripheral vascular disease (PVD) is defined as a chronic progressive atherosclerotic disease leading to partial or total peripheral vascular occlusion.
The disease typically affects the following areas:
Abdominal aorta.
Iliac arteries.
Lower limbs.
Occasionally the upper extremities.
The primary etiology is driven by progressive atherosclerotic disease resulting in the reduction of major organ blood flow and end-organ ischemia.
The process of atherosclerosis is complex and involves numerous cells, proteins, and pathways.
Arterial versus Venous Insufficiency
Arterial Insufficiency Characteristics:
Results in decreased blood flow toward the tissues, producing ischemia.
Pulses are diminished or absent.
Pain is described as sharp and stabbing because of the ischemia; it worsens with activity.
There is interference with nutrients and oxygen going to the tissues.
Can lead to ischemic ulcers.
Specific skin changes occur.
Venous Insufficiency Characteristics:
Results in decreased return of the blood from the tissues to the heart.
Leads to venous congestion and stasis of blood.
Pulses are present.
Leads to edema, skin changes, and stasis ulcers.
Comparison of Arterial and Venous Disorders
Skin:
Arterial: Cool or cold, hairless, dry, shiny, pallor on elevation, rubor on dangling.
Venous: Warm, tough, thickened, mottled, pigmented areas.
Pain:
Arterial: Sharp, stabbing, worsens with activity and walking; lowering feet may relieve pain.
Venous: Aching, cramping; activity and walking sometimes help; elevating the feet relieves pain.
Ulcers:
Arterial: Severely painful, pale with a gray base; found on the heel, toes, or dorsum of the foot.
Venous: Moderately painful, pink base; found on the medial aspect of the ankle.
Pulse:
Arterial: Often absent or diminished.
Venous: Usually present.
Edema:
Arterial: Infrequent.
Venous: Frequent, especially at the end of the day and in areas of ulceration.
Risk Factors for Peripheral Vascular Disorders
Tobacco Use: Nicotine causes vasoconstriction and spasm of the arteries which decreases circulation to the extremities.
Diabetes Mellitus: Changes in glucose and fat metabolism promote the atherosclerotic process.
Hypertension: Causes elastic tissues to be replaced by fibrous collagen tissue; the arterial wall becomes less distensible, increasing resistance to blood flow.
High Cholesterol: Leads to atherosclerotic plaque build-up.
Age: Individuals aged more than years are at higher risk as blood vessels become less elastic, thinner-walled, and calcified.
Elevated Homocysteine Levels.
BMI Greater than : Places added burden on the heart and blood vessels and contributes to venous congestion.
Family History: Genetic history of cardiovascular disease.
Pathophysiology of Atherosclerosis and PVD
Progression and Initial Stages:
Lipoproteins accumulate within the intimal layer of large arteries.
Presence within the endothelium leads to lipid oxidation and a cytokine response with the infiltration of lymphocytes and macrophages.
Macrophages consume these oxidized lipids and form foam cells, leading to the development of "fatty streaks."
Advanced Plaque Formation:
Fatty streaks eventually develop into advanced plaques consisting of necrotic lipid cores and smooth muscle cells (SMC).
SMC and endothelial cells secrete cytokines and growth factors.
SMC migrate to the luminal side of the plaque, leading to extracellular matrix synthesis and the formation of a fibrous plaque.
Vascular Impact:
Plaque accumulation results in vascular stenosis; the body initially uses vascular dilation to maximize end-organ perfusion.
Once dilation capacity is maximized, continued plaque accumulation compromises the lumen, leading to critical narrowing.
Collateral circulatory beds frequently develop to preserve distal perfusion and tissue viability, though they are unable to match healthy vessel blood supply completely.
Ischemia results when blood flow distal to the occlusion is sufficiently compromised, resulting in fixed oxygen delivery that cannot match demand.
Acute Ischemia:
This may occur if vascular thrombosis happens or a cardioembolic source suddenly occludes the narrowed vessel.
Atherosclerotic fibrous plaque rupture exposes subendothelial collagen and inflammatory cells, causing platelet adhesion and aggregation with rapid in-situ thrombosis.
In-situ vascular thrombosis often has better outcomes than embolic causes due to existing collateral circulation.
Embolic Acute Limb Ischemia (ALI) represents of cases, with the femoral artery being the most common site. ALI is a vascular emergency.
Diagnosis and Symbols
Diagnosis can be difficult due to similarly presenting comorbid conditions and many asymptomatic or atypical cases.
Clinical presentation is dependent on the severity of arterial/venous insufficiency.
Symptoms:
Intermittent claudication: Exercise-induced cramping sensation with fatigue, weakness, or pressure.
Pain at rest (sign of severe disease).
Coldness, numbness, or tingling sensations in the limb.
Advanced PAD can lead to necrosis, ulceration, and gangrene starting in the toes and distal foot.
Physical Exam Findings:
Fingernail tar (indicative of cigarette smoking).
Scars from previous vascular surgeries or presence of amputations.
Focused cardiovascular exam: rate, rhythm, and pulse strength.
Assessment for pulselessness, pallor, muscular atrophy, cool or cyanotic skin, or pain with palpation.
Ulcers from arterial insufficiency are tender, have ragged borders, a dry base, and pale or necrotic centers.
Ankle-Brachial Index (ABI):
Cost-effective noninvasive measure for PAD diagnosis.
Calculated by measuring the systolic ankle pressure ratio to the highest systolic brachial pressure.
.
\text{Values} < 0.9 are diagnostic of PAD.
Other Diagnostic Testing:
Duplex Ultrasonography: 2-dimensional imaging with color Doppler.
Magnetic Resonance Angiography (MRA).
Computed Tomography Angiography (CTA).
Treatment and Management of PVD
Management Categories:
Decreasing cardiovascular events.
Improving symptoms.
Lifestyle Modification (Risk Factor Modification):
Smoking cessation (5 A's).
Statin therapy for cholesterol.
Hypertension management.
Diabetic management.
Exercise therapy.
Pharmacotherapy:
Vasodilators: cilostazol and nitrofural (for intermittent claudication management if lifestyle changes fail).
Daily aspirin recommended for overall cardiovascular care.
Revascularization Indicators:
Debilitating symptoms unresponsive to conservative therapy.
Incapacitating claudication interfering with daily activity.
Limb salvage in patients with critical limb ischemia (rest pain, ulceration, gangrene).
Surgical Interventions:
Angioplasty.
Embolectomy.
Endarterectomy.
Arterial by-pass surgery.
Amputation.
Prognosis of PVD
At years:
Nearly of patients will have stable claudication symptoms.
Only to will progress to critical limb ischemia.
to will die within years.
of those deaths are attributed to cardiovascular causes.
Specific Arterial and Venous Disorders
Arterial Disorders:
Thromboangiitis Obliterans (Buerger's Disease): Segmental non-atherosclerotic inflammatory condition affecting small/medium arteries and veins.
Acute phase: Inflammation forms a thrombus.
Subacute phase: Thrombus organizes during ongoing inflammation.
Chronic phase: Inflammation subsides, non-inflammatory fibrotic thrombus forms.
Manifestations: Intermittent claudication, rest pain, coldness, paresthesia, weak/absent pulse (tibial/pedis), cyanosis, gangrene.
Raynaud's Phenomenon/Disease: Intermittent episodes of constriction (spasm) in small arteries of arms or legs causing skin color/temperature changes.
Common in women ages .
Timeline: White (lack of flow) Blue (vessels dilate to keep blood in tissues) Red (flow returns).
Management: Protective clothing, quit smoking, calcium channel blockers, vasodilators, sympathectomy, or amputation for gangrene.
Aneurysm: Localized or diffuse enlargement of an artery.
Types: Saccular (sac-like on one side), Fusiform (spindle-shaped, entire circumference), Dissecting (hemorrhage splits the vessel wall).
Thoracic Aortic Aneurysm: Most common in hypertensive men ages .
Abdominal Aortic Aneurysm (AAA): Most common site (below renal arteries). Presents as a pulsatile abdominal mass.
Arterial Embolism: Blood clots (often plaque fragments) floating in circulation; frequently lodge in femoral or popliteal arteries.
Venous Disorders:
Thrombophlebitis: Inflammation caused by thrombus due to venous stasis, vessel wall damage, or hypercoagulability.
Deep Vein Thrombosis (DVT): Occurs at bifurcations (turbulent flow). Major risk is a pulmonary embolus (PE). Manifests as pain, edema, increased limb circumference, and a positive Homan's sign.
Chronic Venous Insufficiency: Obstruction or reflux of blood back through valves.
Varicose Veins: Abnormally dilated veins with incompetent valves, most common in women ages . Treatment includes vein ligation and stripping.
Hypertension (HTN)
Definition: Pressure in the arteries when the heart contracts and rests. WHO definition: systolic blood pressure (BP) above or diastolic BP above on at least separate occasions.
Importance of Recognition: Each rise in systolic BP increases mortality risk by for heart disease and for stroke.
Classification:
Primary (Essential): of cases; no known cause (idiopathic). Factors: Genetics, obesity, sodium, stress, alcohol, lack of exercise, aging.
Secondary: Identifiable cause such as obstructive sleep apnea, heart defects, kidney disease, adrenal/thyroid conditions, or medications (NSAIDs, contraceptives).
Hypertensive Emergencies:
Crisis: \text{BP} > 180/120\,mmHg.
Emergency: BP elevation with acute target organ damage.
Urgency: BP elevation without acute target organ injury.
Mignant: \text{Diastolic BP} > 130\,mmHg ( in some cases).
Complications: Retinopathy (Grades ), Left Ventricular Hypertrophy (LVH), renal failure, cognitive decline.
Diagnostic Techniques:
Proper measurement: Feet on floor, bare arm, correct cuff size (bladder must circle of arm), arm at heart level, back supported, empty bladder, no conversation.
Confirmation: Ambulatory BP measurement (ABPM) using average of at least measurements or Home BP monitoring (HBPM) for days.
Treatment:
1st Line: Lifestyle modifications (Weight reduction, diet, activity, stop smoking).
2nd Line: Thiazide diuretics (monitor for hypokalemia), ACE inhibitors (monitor for cough), Calcium Antagonists, Beta-blockers, Angiotensin receptor agonists.
Disseminated Intravascular Coagulation (DIC)
Definition: Clinicopathologic syndrome characterized by widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes natural anticoagulant mechanisms.
Pathophysiology:
Either the extrinsic or intrinsic pathway (or both) is activated.
Response to injury generates tissue factor on cell surfaces.
Explosive generation of thrombin depletes clotting factors and platelets.
Fibrinolytic system is activated (Secondary Fibrinolysis), generating FDPs-D-Dimer which inhibits clot formation.
Causes: Obstetric complications (amniotic fluid embolism, eclampsia), malignancies (leukemia), infections (septicemia), snake bites, severe burns.
Classification:
Acute: Rapid; coagulopathy/bleeding dominant; seen in infection or embolism.
Chronic: Slow (weeks); thrombosis/clotting dominant; seen in cancer.
Clinical Manifestations:
Bleeding: Purpura, petechiae, bleeding from IV sites.
Thrombosis: Digital ischemia, renal cortical necrosis, hemorrhagic adrenal infarction.
Lab Findings:
Platelet count: Markedly decreased.
Prothrombin time (PT) and APTT: Increased.
Fibrin degradation products (FDP): Markedly increased.
Fibrinogen: Normal or decreased.
Antithrombin III (AT III) and Protein C: Markedly decreased.
Management:
Treat underlying disorder.
Replace deficiencies: Fresh frozen plasma, platelets, fresh blood.
Anticoagulation: Heparin to inhibit thrombin in specific cases.
Cardiomyopathy Definition and Classification
Cardiomyopathy is a group of diseases that directly affect the structural or functional ability of the myocardium.
Primary cardiomyopathy refers to conditions in which the etiology of the heart disease is known.
Secondary cardiomyopathy refers to conditions in which the etiology of the heart disease is unknown.
WHO Classifications of Cardiomyopathy
Dilated Cardiomyopathy: Characterized by an enlarged heart and systolic dysfunction.
Hypertrophic Cardiomyopathy: Characterized by thickened heart muscle and diastolic dysfunction.
Restrictive Cardiomyopathy: Characterized by myocardial stiffness and diastolic dysfunction.
Arrhythmogenic Right Ventricular (RV) Dysplasia.
Unclassified Cardiomyopathy.
Takotsubo Cardiomyopathy (Broken Heart Syndrome)
This is a non-ischemic cardiomyopathy involving a sudden, temporary weakening of the muscular portion of the heart resulting from extreme emotional or physical stress.
It presents with classic heart attack symptoms, despite having clear coronary arteries.
While the precise cause is unknown, experts believe surging stress hormones, such as adrenaline, "stun" the heart. This triggers changes in heart muscle cells or coronary blood vessels (or both) that prevent the left ventricle from contracting effectively.
Radiographically, an X-ray of the left ventricle shows apical ballooning. During systole, the midsection and tip (apex) of the left ventricle balloon out, while the base contracts normally.
It is named after the tako-tsubo, a round-bottomed, narrow-necked vessel used to catch octopuses, which resembles the shape of the heart during this condition.
Main Risk Factors for Cardiomyopathy
Family history of cardiomyopathy, heart failure, or sudden death.
Having a disease that leads specifically to cardiomyopathy:
Coronary artery disease (CAD).
Previous Myocardial Infarction (MI).
Myocarditis.
Diseases that directly damage the heart muscle:
Hemochromatosis: A condition involving excessive iron deposition in the tissues.
Sarcoidosis: An inflammatory disease producing tiny lumps of cells in various organs, including the heart.
Amyloidosis: A disease where abnormal proteins are deposited in heart tissue.
Alcoholism.
Hypertension (HTN).
Diabetes.
Dilated Cardiomyopathy
This condition results from damage to cardiac muscle fibers, which causes a loss of muscle tone.
Loss of muscle tone grossly dilates all four chambers of the heart, giving the heart a globular shape.
The heart's ability to pump blood is decreased because the left ventricle (LV) is weakened and enlarged.
Causes of Dilated Cardiomyopathy
Viral or bacterial infection (myocarditis).
Hypertension.
Peripartum syndrome (related to toxemia).
Ischemic heart disease or valvular disease.
Drug hypersensitivity or chemotherapy.
Cardiotoxic effects of drugs or alcohol.
Genetic factors.
Muscular Dystrophy: Characterized by the weakening and wasting of muscles.
Pathophysiology of Dilated Cardiomyopathy
Extensive damage to fibers from diffuse inflammation and rapid degeneration of myocardial fibers causes ventricular dilation.
This reduces contractility in the left ventricle, leading to impaired systolic function.
As systolic function declines, stroke volume (SV), ejection fraction (EF), and cardiac output (CO) fall.
The decline leads to atrial enlargement and the stasis of blood in the left ventricle.
The ultimate physical result is cardiomegaly.
It can affect other organ systems, such as the lungs and liver.
Signs and Symptoms of Dilated Cardiomyopathy
Initial Symptoms:
Shortness of breath.
Orthopnea.
Dyspnea on exertion (DOE).
Paroxysmal nocturnal dyspnea (PND).
Fatigue.
Dry cough at night.
Progressive Symptoms:
Peripheral edema and weight gain.
Hepatomegaly.
Jugular vein distention (JVD).
Peripheral cyanosis.
Tachycardia or bradycardia.
Pansystolic murmur or and gallop rhythms.
Irregular pulse if atrial fibrillation is present.
Hypertrophic Cardiomyopathy
This is characterized by disproportionate, asymmetrical thickening of the interventricular septum and left ventricular hypertrophy (LVH).
It involves LV hypertrophy without ventricular dilation.
Hypertrophic obstructive cardiomyopathy occurs when the septum between the two ventricles becomes enlarged and obstructs blood flow from the left ventricle.
It is the leading cause of sudden cardiac death in young athletes.
Causes of Hypertrophic Cardiomyopathy
Autosomal dominant inheritance (genetic).
Aortic stenosis.
Hypertension.
Obstructive valvular disease.
Thyroid disease.
Pathophysiology of Hypertrophic Cardiomyopathy
Hypertrophy of the left ventricle and interventricular septum obstructs left ventricular outflow.
The heart attempts to compensate for decreased cardiac output by increasing the rate and force of contractions.
The hypertrophied ventricle becomes stiff and unable to relax and fill during diastole (diastolic dysfunction).
As left ventricular volume diminishes and filling pressure rises, pulmonary venous pressure increases, leading to venous congestion and dyspnea.
Signs and Symptoms of Hypertrophic Cardiomyopathy
Angina, syncope, dyspnea, dyspnea on exertion, or fatigue.
Systolic ejection murmur located along the left sternal border and at the apex.
Pulsus bisferiens or an abrupt arterial pulse.
Irregular pulse if atrial fibrillation is present.
Restrictive Cardiomyopathy
This is characterized by restricted ventricular filling due to decreased ventricular compliance and endocardial fibrosis and thickening.
If the condition is severe, it is irreversible.
Systolic function typically remains unaffected; however, the walls of the ventricles become stiff (though not necessarily thickened).
It is generally considered the least common type of cardiomyopathy.
Causes of Restrictive Cardiomyopathy
Amyloidosis or sarcoidosis.
Hemochromatosis.
Infiltrative neoplastic disease.
Post-radiation fibrosis.
Noninfiltrative causes (familial, idiopathic).
Storage diseases (Fabry disease).
Endomyocardial fibrosis.
Pathophysiology of Restrictive Cardiomyopathy
Endocardial fibrosis and hypertrophy limit myocardial contraction and emptying during systole, as well as ventricular relaxation and filling during diastole.
Decreased ventricular compliance causes the ventricles to become resistant to filling.
This resistance leads to a fall in cardiac output.
Signs and Symptoms of Restrictive Cardiomyopathy
Fatigue, dyspnea, dyspnea on exertion, and orthopnea.
Syncope, chest pain, and peripheral edema.
Liver engorgement and ascites.
Jugular vein distention (JVD).
Peripheral cyanosis and pallor.
or gallop rhythms or systolic murmurs.
Arrhythmogenic Right Ventricular Cardiomyopathy
This is an inherited disease of the cardiac muscle characterized by autosomal dominant inheritance.
It results in right ventricular (RV) failure.
Rhythm disturbances include ventricular tachycardia (VT) and ventricular fibrillation (VF).
Pathologically, the right ventricular wall is thinned with extensive fatty infiltration and fibrosis.
Diagnostics for Cardiomyopathy
Patient history.
Chest X-ray: Used to identify cardiomegaly and increased heart size.
Echocardiography.
Cardiac catheterization.
Electrocardiography (ECG): Usually shows:
Left ventricular hypertrophy.
ST-segment and T-wave abnormalities.
Q waves in leads II, III, aVF, and in V4 to V6.
Left anterior hemiblock.
Left axis deviation.
Ventricular and atrial arrhythmias.
Treatment and ManagementLifestyle Modifications
Quitting smoking.
Avoiding alcohol.
Eating a low-fat, low-salt diet.
Restricting fluids.
Regular exercise and enough sleep.
Reducing stress.
Goals of Treatment
Manage underlying conditions.
Control symptoms.
Reduce progression of the disease.
Reduce complications to avoid sudden death.
Medications for Symptom Management
Goal | Medication Types |
|---|---|
Lower Blood Pressure | ACE inhibitors, Angiotensin II receptor blockers, Beta-blockers, Calcium channel blockers |
Slow Heart Rate | Beta-blockers, Calcium channel blockers, Digoxin |
Maintain Normal Rhythm | Antiarrhythmics |
Remove Fluid/Sodium | Diuretics |
Prevent Blood Clots | Anticoagulants |
Reduce Inflammation | Corticosteroids |
Surgical Interventions by Cardiomyopathy Type
Dilated Cardiomyopathy: Cardioversion, Pacemaker, Implantable Cardioverter Defibrillator (ICD), Valve repair or replacement, Heart transplant.
Hypertrophic Cardiomyopathy: Cardioversion, Pacemaker, ICD, Valve repair or replacement, Heart transplant, Septal Ablation, Ventricular myotomy, or septal myectomy.
Restrictive Cardiomyopathy: Heart transplant.
Cardioversion vs. DefibrillationCardioversion
Status: Elective procedure.
Synchronization: "Synch On" (synchronized with the "QRS" complex).
Patient State: Awake and frequently sedated.
Energy: .
Requirements: Signed consent form and EKG monitor.
Defibrillation
Status: Emergency procedure.
Synchronization: "Synch Off".
Indications: V-Fib or V-Tach (no cardiac output).
Patient State: Unconscious.
Energy: Begins with , up to .
Requirements: Call a code and EKG monitor.
Implantable Devices
Implantable Cardioverter Defibrillator (ICD): Contains pacing leads and a battery generator; leads may be placed in the RAA (Right Atrial Appendage) or the RV (Right Ventricle) apex.
Pacemaker: Used to regulate cardiac rhythm.
Complications and Prevention
Complications:
Heart failure.
Blood clots.
Valve problems.
Cardiac arrest and sudden death.
Prevention:
Avoid alcohol.
Control Hypertension (HTN) and cholesterol levels.
Maintain a healthy diet and exercise regularly.
Ensure adequate sleep and stress reduction.
Fundamental Principles of Atmospheric Pressure and Altitude
Atmospheric conditions are categorized by their relationship to sea level pressure:
Normobaric (At Sea Level): Equivalent to one atmosphere () or .
Hypobaric (Above Sea Level): Conditions where the ambient pressure is less than .
Hyperbaric (Below Sea Level): Conditions where the ambient pressure is greater than .
The composition of air remains constant regardless of altitude or pressure changes:
Fraction of Inspired Oxygen (): ()
Fraction of Nitrogen (): ()
Fraction of Carbon Dioxide (): ()
Trace Elements: Argon, Neon, Krypton, Hydrogen, Xenon, Ozone, and Radon.
Hypobaric Conditions and Altitude Dynamics
Physical changes associated with increasing altitude:
Gravitational pull decreases.
Gas molecules move further apart.
Air density decreases.
Molecule collisions decrease.
Atmospheric pressure decreases.
Specific Pressure Changes in Hypobaric Conditions:
At : ; .
At : ; .
At : ; .
At : ; .
At : ; .
At : ; .
Definition of Hypobarism: A condition occurring when ambient pressure is lower than the pressure of gases within the body. It is marked by the distension of bodily cavities, the release of gas bubbles within tissues, and a general decrease in atmospheric pressure at altitude.
Physiological Responses to Altitude
Blood Gas Changes by Altitude (Meters and Feet):
Sea Level: ; ; .
(): ; ; .
(): ; ; .
(): ; ; .
(): ; ; .
(): ; ; .
(): ; ; .
Acclimatization: The process of physiological adaptation to decreased atmospheric oxygen content, including:
Increased rate and depth of breathing.
Increased production of Red Blood Cells (RBCs).
Increased renal excretion of bicarbonate as a response to respiratory alkalosis.
Oxygen Availability and Performance: Hemoglobin saturation and oxygen uptake are significantly impaired at increased altitudes.
Zonal Classifications of Altitude
High Altitude ( to ): Acute Mountain Sickness (AMS) begins to manifest here, typically starting with headaches and altered night vision.
Very High Altitude ( to ): Significant indications of altitude sickness occur from onward, including tingling sensations, fatigue, and headaches.
Extreme Altitude (Over ): Unconsciousness is likely if an individual is not properly acclimatized. Very few mountain ranges reach this level.
The Death Zone (Above ): Oxygen concentration is too low for cells to build new tissue. The body continually withers until death occurs.
Altitude-Related Pathologies
Acute Mountain Sickness (AMS):
Etiology: Hypoxemia.
Risk factors: Rapid ascent, physical exertion, age under years, obesity, and pre-existing cardiac or lung disease.
Typically occurs above in non-acclimatized individuals.
Signs/Symptoms: Appear within hours, peak at hours, and lessen after hours. Includes severe fatigue, muscle strength loss, dizziness, confusion, insomnia, Shortness of Breath (SOB), and paroxysmal nocturnal dyspnea. Symptoms worsen at night due to decreased respiratory drive.
High Altitude Pulmonary Edema (HAPE):
A potentially fatal condition involving fluid accumulation in the lungs.
Symptoms: Breathlessness at rest, chest tightness, coarse crackles, and a cough that progresses from dry to pink and frothy.
Pathophysiology: Hypoxemia leads to increased sympathetic activity, pulmonary artery pressure, and uneven vasoconstriction, causing regional overperfusion, capillary leakage, and edema.
High Altitude Cerebral Edema (HACE):
Considered the end-stage of AMS; brain swelling due to fluid.
Symptoms: Ataxia, altered consciousness, visual disturbances, papilledema, retinal hemorrhages, and drowsiness followed by stupor.
Pathophysiology: Hypoxemia causes brain vasodilation, increased Cerebral Blood Volume (CBV) and Cerebral Blood Flow (CBF), leading to impaired autoregulation, overperfusion, and vasogenic edema.
Medical and Therapeutic Management of Hypobarism
Treatment Strategies:
Mild AMS: Cessation of further ascent.
Moderate to Severe AMS: Oxygen administration, rapid descent ( or more), Gamow bag usage, and acetazolamide.
HAPE: Immediate descent, oxygen inhalation, Gamow bag, and nifedipine.
HACE: Immediate descent, Gamow bag, high-dose steroids (dexamethasone), diuretics, and mannitol.
Gamow Bag: An impermeable bag inflated to simulate lower altitudes, capable of generating above ambient pressure.
Prevention and Acclimatization:
Proper acclimatization takes days, allowing erythropoietin to stimulate RBC production.
Rules of thumb: Ascend slowly, climb high and sleep low, stop if symptoms appear, descend if symptoms worsen, maintain hydration, and avoid overexertion.
Protective Medications:
Diamox (Acetazolamide): A carbonic anhydrase inhibitor and diuretic. It induces relative metabolic acidosis to stimulate further respiratory drive.
Dexamethasone: A corticosteroid used to decrease inflammation; must be started days prior to ascent to prevent HAPE and HACE.
Hyperbaric Conditions and Pressure Dynamics
Definition of Hyperbarism: High atmospheric pressure disturbances where external ambient pressure is greater than sea level pressure (>760\,\text{mmHg}).
Pressure Changes Below Sea Level:
At : (); .
At : (); .
At : (); .
At : (); .
Henry's Law: The solubility of a gas in a liquid is directly proportional to the pressure of that gas above the liquid. Solubility increases by decreasing temperature or increasing pressure.
Pathologies of High Pressure
Nitrogen Narcosis (Rapture of the Deep):
Caused by breathing compressed nitrogen at deep depths, acting as an anesthetic on the Central Nervous System (CNS).
Symptoms: Impaired judgment, euphoria (similar to alcohol intoxication), hallucinations, stupor, and coma.
Management: Limit depth of compressed air diving to . For depths beyond , use helium-oxygen mixtures, as helium lacks narcotic effects.
Decompression Sickness (DCS or "The Bends"):
Occurs when dissolved gases (nitrogen or helium) exit solution and form bubbles in the body during depressurization (ascent).
Classification:
Type I: Affects skin, musculoskeletal system (joint pain), or lymphatic system.
Type II: Affects the CNS. Signs include substernal discomfort, tachypnea, right heart strain, paralysis, and convulsions.
Mechanism: Bubble formation leads to vessel obstruction, mechanical tissue distortion, and endothelial activation (capillary leak).
Arterial Gas Embolism (AGE):
A severe form of barotrauma where gas bubbles enter the arterial circulation through the alveolar-capillary membrane.
Suspect AGE if a diver loses consciousness on ascent or within minutes of surfacing.
Management: Immediate oxygen, place the patient in a supine position, and transfer to a hyperbaric oxygen (HBO) facility.
Clinical Management of Hyperbaric Pathologies
Initial Treatment: oxygen and fluid administration to minimize dehydration.
HBO Therapy: Hyperbaric oxygen therapy is required for neurological, pulmonary, or mottled skin lesions even if symptoms appear days later.
Positioning: While Trendelenburg and left lateral decubitus positions were historically used for air emboli (Durant's maneuver), they are no longer recommended for long periods due to cerebral edema risks.
Complications: Large volumes of venous bubbles can cause lung damage or enter arterial circulation via a cardiac right-to-left shunt, such as a Patent Foramen Ovale (PFO), which is present in of the population
.
Definition and General Overview of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis () is a progressive neurodegenerative disease that causes the degeneration and eventual death of motor neurons in the brain and spinal cord.
Because of this degeneration, patients experience muscle atrophy, loss of movement, and progressive paralysis.
The disease is also widely known as Lou Gehrig's disease.
Progressive muscle weakness eventually leads to death due to the failure of vital muscles responsible for eating, swallowing, and breathing.
Notably, the disease does not alter the mind or the senses.
Classifications of ALS
Cause Classification:
Familial (genetic) : This is inherited through a genetic mutation passed through a parent. It accounts for about of cases.
Sporadic (non-hereditary) : These cases occur without a family history, though patients often carry smaller genetic variations that increase susceptibility.
Site of Onset Classification:
Limb-onset : The earliest symptoms present as muscle weakness or stiffness in the arms, hands, legs, or feet.
Bulbar-onset : Initial symptoms involve the muscles of the head, face, and neck. This evolves into early issues with slurred speech, a hoarse voice, and difficulty swallowing.
Respiratory-onset : This is a rare presentation where the diaphragm and intercostal muscles are the first to be affected. It is considered the rarest form.
Motor Neuron Classification:
Classic : Characterized by the deterioration of both upper and lower motor neurons.
Progressive Muscular Atrophy: This form affects only the lower motor neurons.
Primary Lateral Sclerosis: This form affects only the upper motor neurons.
Risk Factors and Epidemiology
Age: The risk for developing rises steadily with age, with the highest incidence occurring between years of age.
Genetics: Approximately of cases are hereditary, but smaller genetic variations are relevant even in sporadic cases.
Sex: Before the age of , men are slightly more likely to develop than women.
Race and Ethnicity: Studies indicate that is more prevalent in white populations compared to other groups.
Smoking: Research indicates that smocking is an environmental risk factor for the disease.
Military Service: Veterans have a roughly times higher risk of developing , which is thought to be linked to potential trauma or exposure during service.
Toxin Exposure: Prolonged exposure to certain environmental toxins, including pesticides, heavy metals (such as lead and mercury), and solvents, has been statistically linked to a higher risk.
Head Trauma: A history of traumatic brain injuries or repeated head trauma is associated with an elevated risk.
Etiology and Anatomical Pathology
Etiology: In most cases, the cause is unknown. Researchers believe it develops from a complex interaction of genetic and environmental factors that trigger the death of motor neurons in the brain and spinal cord.
Anatomical Areas Impacted:
Motor Cortex and Upper Motor Neuron Degeneration: Degeneration occurs mostly in the Betz cells. This is accompanied by the hardening (sclerosis) of the corticospinal and corticobulbar tracts, visible via advanced imaging as white matter degeneration.
Spinal Cord and Brainstem (Lower Motor Neuron Degeneration): There is progressive loss of alpha motor neurons in the anterior horn cells of the spinal cord and the motor nuclei of the lower brainstem. Alphas motor neurons are a specific type of lower motor neuron responsible for generating the physical force that moves muscles.
Neuromuscular Junctions: The loss of motor neuron axons leads directly to the retraction of nerve terminals, resulting in the denervation of skeletal muscles.
Skeletal Muscle Denervation and Atrophy: Striated muscle undergoes structural shrinkage and fiber-type grouping because they lose their innervating nerve. Fiber type grouping is an abnormal arrangement of muscle fibers in which similar fiber types cluster together in large bundles, rather than maintaining their normal, scattered \"checkerboard\" distribution.
Muscle Metabolism: Muscles show signs of mitochondrial dysfunction and abnormal glycogen/lipid metabolism that contribute to disease progression. Lack of nerve stimulation leads to muscle atrophy (muscles becoming smaller and weaker).
Molecular Pathophysiology and Mechanism
Glutamate Function: Glutamate is a primary excitatory neurotransmitter responsible for central nervous system function, memory learning, and motor nerve signaling. It is synthesized within the brain.
Normal Signaling Process:
Glutamate is released from the synaptic neuron into the cleft.
Post-synaptic receptors (AMPA and NMDA) initiate an action potential by triggering the release of sodium and calcium ions.
Astrocytes (glial cells) and EEAT2 (excitatory amino acid transporter ) help stop excitation and recycle glutamate.
The enzyme glutaminase at the end of post-synaptic neurons converts it to glutaminase and it is recycled back to the neuron.
ALS Pathological Mechanism:
In , EEAT2 is not recruited, causing astrocytes to fail in the reuptake and recycling of glutamate to the post-synaptic neuron.
Consequently, AMPA and NMDA receptors are continually excited.
This leads to an overload of calcium ions flooding the neuron, known as excitotoxicity.
Excitotoxicity causes oxidative damage to the mitochondria within motor neurons, leading to apoptosis of cells in the upper and lower neurons.
Signs and Symptoms
Early Signs and Symptoms:
Muscle twitching (fasciculations) in the arms and legs.
Imbalance or pronounced clumsiness.
Falling.
Outbursts of laughing or crying (a physical reflex issue).
Altered thinking and behavior.
Slurring of speech.
Stiffness.
Muscle atrophy.
Late Stage Progression: Muscles responsible for moving, eating, speaking, and breathing progressively weaken.
Management and Lifestyle Assistance
Management of Progression: Patients require various aids for basic life functions as the disease progresses.
Nutrition: A feeding tube can be inserted to assist with eating.
Respiratory Assistance: BIPAP (Bi-level Positive Airway Pressure) for breathing support; Diaphragm pacers to stimulate diaphragm contraction and reduce reliance on mechanical ventilation.
Mobility: Ramps built into the home and wheelchairs.
Patient Autonomy: Lifestyle aids such as utensil adaptations and button aids.
Communication: Voice banking and eye-tracking devices.
Treatment Interventions
Medical Objectives: The primary objective is to lessen glutamate excess, reduce cellular damage, and slow disease progression.
Pharmacological Medication:
Riluzome (Rilutek): An FDA-approved drug available in pill form or thick liquid for those with swallowing issues. Side effects include fatigue and liver disease.
Mexiletine: Used to help reduce muscle cramps by decreasing the sensitivity of neurons to action potentials.
Glycopyrrolate: Used to reduce excess salivary secretions.
Diet and Exercise:
Objective: Maintain muscle mass to prevent atrophy and keep strength for as long as possible.
Omega fatty acids: Used to maintain cellular and brain health.
Protein-rich foods (e.g., fish and nuts): Used to maintain cellular health and muscle mass.
Physiotherapy: Exercises to maintain mobility, lessen joint stiffness, and slow the damage of neurons.
Prognosis
General Outlook: There is no known cure for .
Life Expectancy: Generally years after diagnosis.
Survival Statistics:
of patients live for at least years post-diagnosis.
of patients live for years post-diagnosis.
of patients live for at least years post-diagnosis.
Prognostic Factors:
Limb-onset typically has a slower progression than bulbar or respiratory onset because it does not initially affect muscles vital to life.
Diagnosis after age is associated with a faster decline compared to those diagnosed before age .
Role of the Respiratory Therapist (RT) in Management
Pulmonary Lung Function Tests (PFTs): Administered to assess and test muscle weakness.
BIPAP (Bi-level Positive Airway Pressure): Used to support breathing with positive pressure and clear retention.
Tracheostomies: Installed to help clear lung secretions and obstructions using suction and cough assists.
SNIP (Sniff Nasal Inspiratory Pressure): Measures the strength of the diaphragm by measuring peak pressure inside the nose during a maximal sniff.
Lung Volume Recruitment: Promotes breath stacking, which can prevent lung collapse and increase the usable lung area.
Overview of Congestive Heart Failure
Congestive heart failure (CHF) is a clinical condition characterized by the weakening of the heart muscle. This weakening reduces the heart's effectiveness in pumping blood to the lungs and various tissues throughout the body. A primary consequence of this reduced pumping capacity is the development of different types of edemas (fluid accumulation) in various regions of the body.
Signs and Symptoms
Individuals with congestive heart failure may present with a wide range of clinical manifestations, including:
Shortness of breath, which occurs during physical activity or specifically when lying down.
Generalized fatigue and weakness.
Swelling (edema) localized in the legs, ankles, and feet.
Heart rhythm abnormalities, such as a rapid or irregular heartbeat.
A noticeable reduction in the ability to engage in physical exercise.
Wheezing sounds during respiration.
A persistent cough that does not resolve, which may produce white or pink-tinged mucus containing spots of blood.
Swelling in the abdominal or belly area.
Very rapid weight gain resulting from the buildup of fluids.
Nausea and a lack of appetite.
Cognitive difficulties, including trouble concentrating or decreased levels of alertness.
Chest pain, particularly in cases where the heart failure is a direct result of a heart attack.
Clinical History and Assessment Questions
When obtaining a patient history to assess for CHF, several critical questions must be addressed:
Does the patient smoke or have they been exposed to second-hand smoke?
Does the patient have a previous medical diagnosis that could contribute to the development of CHF? Examples include Chronic Obstructive Pulmonary Disease (COPD), diabetes, angina, or any form of prior heart damage.
Does the patient drink alcohol routinely?
Is the patient currently taking any medications that could potentially exacerbate CHF symptoms?
Etiology and Risk Factors
Several factors increase the risk of developing congestive heart failure:
Age: Individuals older than 65 are at a higher risk.
Substance Use: Use of tobacco products, cocaine, or alcohol.
Lifestyle: Maintaining an inactive or sedentary lifestyle.
Dietary Habits: Regular consumption of foods high in salt and fat.
Medical Conditions: Having high blood pressure (hypertension), coronary artery disease, or a history of heart attacks.
Genetics: A family history of congestive heart failure.
Physical Examination Findings
Clinicians may observe the following during a physical exam of a patient with CHF:
Shortness of breath specifically during activity.
Fatigue of such severity that the patient is unable to perform exercise.
Orthopnea: Shortness of breath that occurs when the patient is lying down.
Nocturnal coughing (coughing at night).
Observations of reduced appetite.
Manifestations of edema.
Pathophysiology and Classification
Congestive heart failure can stem from issues related to cardiac structure, rhythm, or function.
Mechanism of Weakening: When the heart is unable to pump blood efficiently, the body attempts to compensate, causing the heart to work harder. This increase in effort eventually leads to the death of heart cells and a subsequent weakening of the heart.
Hormonal Response: The body produces hormones that cause blood vessels to narrow. This response also leads to the retention of water and salt, creating edema in the extremities, lungs, or other internal organs.
Directional Classification: CHF is categorized into right-sided or left-sided heart failure. Left-sided failure is the most common form.
Right-sided heart failure: The heart is unable to dilate its vessels properly.
Left-sided heart failure: The heart is unable to constrict its vessels properly.
Subdivisions of Left-Sided Failure:
Systolic failure: The left ventricle is unable to contract properly, which leads to a decreased ejection fraction.
Diastolic failure: The left ventricle is unable to relax properly, which leads to an increased ejection fraction.
Diagnostic Investigations
Various tests are utilized to confirm a diagnosis of heart failure and identify its underlying causes:
Blood Tests: These help identify diseases affecting the heart and measure specific proteins produced by the heart and blood vessels. In cases of heart failure, the levels of these proteins typically increase.
Chest X-ray: Used to visualize the condition and size of the heart and lungs.
Electrocardiogram (ECG or EKG): A painless test that records the heart's electrical signals, showing the speed and rhythm of the heartbeat.
Echocardiogram: Uses sound waves to create images of the heart in motion. It reveals the size and structure of the heart and valves, as well as blood flow patterns.
Ejection Fraction: Measured during an echocardiogram, this is the percentage of blood leaving the heart each time it squeezes (contracts).
A measurement of or higher is considered ideal.
Heart failure can still be present even if the ejection fraction is within the ideal range.
This result is vital for classifying the failure type and guiding treatment.
Exercise or Stress Tests: Monitoring the heart while the patient walks on a treadmill or rides a stationary bike to see how the heart responds to physical exertion. Medicines may be used to simulate exercise if the patient is unable to perform the physical task.
Cardiac CT Scan: Uses X-rays to create cross-sectional heart images.
Cardiac MRI: Uses magnetic fields and radio waves for highly detailed heart imaging.
Coronary Angiogram: Identifies blockages in heart arteries. A catheter is inserted into a blood vessel (usually in the wrist or groin) and guided to the heart. Dye is released to make arteries visible on X-ray and video.
Myocardial Biopsy: The removal of small heart muscle pieces for examination, often used to diagnose specific heart muscle diseases causing failure.
Disease Staging: Following testing, a healthcare provider will determine the stage of the disease to decide on the most appropriate treatment plan.
Management and Treatment Strategies
While there is no cure for CHF, symptoms can be managed, and the progression of heart weakening can be slowed through various interventions:
Pharmacological Treatments:
Vasodilators: Used to reduce blood pressure and dilate blood vessels.
Diuretics: Encourage the body to expel excess fluid.
Aldosterone inhibitors: Reduce fluid retention and increase life expectancy.
Digitalis glycosides: Help the heart perform more forceful contractions.
ACE inhibitors and Beta blockers: Both classes are used to improve heart function and increase life expectancy.
Surgical and Device Interventions:
Surgeries to open blocked arteries or replace heart valves.
Biventricular Pacemaker: Helps both sides of the heart work in synchronization.
Ventricular Assist Device (VAD): Often used in conjunction with a pacemaker, this device helps the heart move blood from the lower chambers to the rest of the body.
Heart Transplant: Reserved for cases where other treatments have failed and the patient is a viable candidate.
Potential Complications
Congestive heart failure can lead to several serious systemic complications:
Impaired kidney function.
Pulmonary edema (fluid in the lungs).
Respiratory distress.
Blood clots, resulting from blood vessel constriction.
Potential liver-related issues.
Role of the Respiratory Therapist (RT)
Respiratory Therapists play a vital role when heart failure intersects with other respiratory conditions such as asthma or COPD. These conditions cause the airways to narrow in a manner unique from heart failure-induced shortness of breath. The RT provides tailored breathing treatments and administers respiratory medicines designed to swiftly open constricted airways, providing rapid relief to the patient.
Overview of Guillain-Barre Syndrome (GBS)
Guillain-Barre Syndrome (GBS) is categorized as a rare, acute, and rapidly progressive motor neuron disease.
The condition occurs when the body’s immune system mistakenly attacks the peripheral nerves.
The underlying mechanism involves a cell-mediated humoral immunologic reaction.
This reaction leads to several reversible pathological changes, including:
Inflammation
Demyelination
Degeneration of the spinal nerves and nerve roots
Despite its severity, GBS is a treatable condition, and the majority of individuals eventually achieve a full recovery.
Signs and Symptoms
Muscle weakness is a primary characteristic of the syndrome.
Sensory changes are common, including numbness or altered sensation.
Pain is often localized in the back or the legs.
Cranial nerve impairment may be present.
Coordination issues frequently occur, affecting balance and motor control.
Autonomic nervous system instability can manifest through various systemic issues:
Fluctuating blood pressure
Cardiac arrhythmias
Loss of sweating capability
Digestive problems
Urinary issues
Pediatric variations exist; children may experience difficulty walking or may outright refuse to walk.
Clinical Examination and History Questions
Critical questions for medical history include:
Have you had a recent respiratory or gastrointestinal illness?
Have you eaten raw or undercooked poultry recently?
Have you undergone any surgeries or received vaccinations in the past few weeks?
When did your symptoms first begin and how have they progressed?
Did your weakness or tingling start in your feet/legs and move upward?
Exam findings typically reveal the following:
Symmetrical ascending muscle weakness or a lack of muscle control in the limbs.
Areflexia, which is the absence of reflexes.
Facial asymmetry or droopiness.
Slowed pupil reactions.
Unsteady gait or poor balance.
Irregular heartbeats.
Fluctuating blood pressure.
Etiology and Risk Factors
The precise cause of GBS remains unknown, though it is most likely an abnormal, misdirected immune response.
Risk factors include:
Preceding infections, most notably Campylobacter jejuni.
Recent surgical procedures.
Demographic factors such as being male.
Age: Indivudals with an age >50.
Genetics: While not common, certain genetic markers such as CD1A and CD1E are sometimes involved.
Pathophysiology
The syndrome is usually triggered by a respiratory infection (e.g., cold, cough, sore throat, or flu-like symptoms) or a gastrointestinal (GI) infection (e.g., diarrhea, nausea, or vomiting).
An autoimmune response occurs where antibodies produced by the immune system attack the peripheral nerves.
This attack causes delayed nerve conduction and demyelination.
Pathological activity mostly occurs in:
Peripheral nerves
Spinal roots
Cranial nerves (occasionally)
The damage results in:
Spontaneous conduction, which creates a numbness or tingling feeling.
Loss of reflexes and muscle weakness, which eventually leads to paralysis.
Investigations and Diagnosis
Clinical Assessment: Diagnosis is based on a detailed patient history and the evaluation of symmetrical ascending weakness paired with areflexia.
Cerebrospinal Fluid (CSF) Analysis: Obtained via lumbar puncture, this reveals albuminocytologic dissociation. This is defined as a state where the CSF contains elevated protein levels but a normal white blood cell (WBC) count.
Electrophysiological Studies:
Nerve Conduction: This measures the speed of electrical signals through the nerve to confirm myelin damage and the presence of slowed conduction.
Electromyography: This uses needle electrodes to measure electrical activity in the muscles. These studies are essential for distinguishing specific subtypes of GBS.
MRI: This imaging is utilized to look at the brain and spinal cord to rule out other potential causes of acute muscle weakness.
Management and Treatment
Immunoglobulin Therapy:
Involves the intravenous injection of IVIG.
This therapy blocks the immune system's attack on the peripheral nerves and promotes healing.
Benefits include speeding up recovery, reducing the length of stay in intensive care, regaining strength faster, and reducing the need for mechanical ventilation.
Plasma Exchange:
This process involves separating and removing plasma that contains toxins and antibodies from the blood.
A replacement fluid solution is mixed with the remaining blood sample and then put back into the body.
Complications
Acute Respiratory Distress Syndrome (ARDS) or respiratory compromise.
Increased heart rate (HR).
Blood pressure that is either too high or too low.
Gastrointestinal dysmotility.
Respiratory Therapy (RT) Management
Mechanical ventilation may be required if paralysis reaches the respiratory muscles, including the diaphragm and intercostal muscles.
Paralysis of these muscles causes difficulty breathing, leading to:
A build-up of
A drop in
RT goals include protecting the airway and managing clinical parameters such as:
Respiratory Rate (RR)
Definition and Classifications of Aortic Dissection
Definition of the Disease Process: Aortic dissection is a severe medical condition characterized by a tear in the inner layer of the aorta. The aorta is the large blood vessel that branches off from the heart. When a tear occurs, it allows blood to flow between the structural layers of the aortic wall, forcing these layers apart. This process typically results in a life-threatening emergency.
Stanford Classification System:
Type A: This classification involves the ascending aorta, the aortic arch, and potentially the descending aorta. It is a critical condition that requires immediate surgical intervention.
Type B: This classification involves only the descending aorta. It is frequently managed with medical treatment unless specific complications arise.
DeBakey Classification System:
Type I: This type originates in the ascending aorta and propagates at least as far as the aortic arch, often extending distally beyond it.
Type II: This type originates in the ascending aorta and remains strictly confined to that section.
Type III: This type originates in the descending aorta and can extend either distally or proximally.
Risk Factors and Preventative Measures
Primary Risk Factors:
Hypertension: High blood pressure is identified as the most significant risk factor for the development of aortic dissection.
Connective Tissue Disorders: Genetic conditions such as Marfan syndrome and Ehlers-Danlos syndrome significantly increase risk.
Atherosclerosis: The buildup of plaque in the arteries contributes to the weakening of the vessel walls.
Aortic Aneurysm: The presence of an existing aneurysm can predispose an individual to a dissection.
Age: The condition is most commonly diagnosed in individuals between the ages of .
Gender: Aortic dissection is found to be more common in men.
Family History: A genetic predisposition within a family can increase an individual's risk level.
Cocaine Use: Use of this substance can lead to acute hypertension, triggering a dissection.
Trauma: Blunt trauma to the chest can lead to the tearing of the aortic wall.
Prevention Strategies:
Control Blood Pressure: This involves regular monitoring and the active management of hypertension.
Healthy Lifestyle: Adopting a diet and exercise regimen to prevent the onset of atherosclerosis.
Avoidance of Stimulants: Refraining from the use of cocaine and other stimulants.
Regular Monitoring: Consistent medical follow-ups for individuals with a known family history or diagnosed connective tissue disorders.
Etiology and Pathophysiological Mechanisms
Etiology: Aortic dissection typically arises from a combination of high blood pressure and a pre-existing weakness in the aortic wall. High pressure forces the inner layer to tear, allowing blood to enter the wall and create a secondary channel.
Anatomic Alterations and Pathophysiology:
The tear in the inner layer creates a "false lumen" alongside the original path of the aorta.
As blood divides and flows into the false lumen, it diverts blood away from the "true lumen."
This division reduces the blood supply required by all organs, thereby decreasing overall oxygen delivery.
The true lumen of the aorta is typically narrower than the false lumen, which forms within the middle layer of the vessel wall.
The accumulation and flow of blood within the false lumen can cause a bulge in the artery wall, known as an aneurysm. This bulge significantly increases the risk of a complete arterial rupture.
Clinical Presentation and Manifestations
Symptom Onset: Symptoms typically begin suddenly and with great intensity.
Key Manifestations:
Chest Pain: Described as sharp, stabbing, or tearing. This pain is not localized and can radiate to the back, neck, jaw, arms, or even the abdomen.
Fainting: Loss of consciousness due to circulatory compromise.
Shortness of Breath: Difficulty breathing following the onset of the dissection.
One-Sided Weakness: Neurological deficits or weakness appearing on one side of the body.
Sweating: Profuse sweating often accompanies the acute pain and shock.
Management and Therapeutic Options
Surgical Interventions:
Type A Dissection: This type almost always requires surgical repair as a standard of care.
Type B Dissection: While typically managed medically, surgery may be considered for complicated cases. A less invasive option, endovascular stent-grafting, is often used for Type B cases.
Non-Surgical/Medical Management:
Regular Checkups: Continuous monitoring of blood pressure and heart rate.
Pain Relief: The use of analgesics, specifically mentioning painkillers such as morphine.
IV Beta-Blockers: These are utilized to achieve an ideal heart rate of approximately and to strictly control blood pressure.
Prognosis and Clinical Outcomes
Type A (Ascending Aorta Dissection):
This is the most severe form and constitutes a surgical emergency.
It carries a high risk of life-altering complications, including myocardial infarction (heart attack), stroke, and aortic rupture.
The surgical mortality rates range from .
Without surgical intervention, the mortality rate increases by for every hour that passes after the onset of symptoms.
Type B (Descending Aorta Dissection):
This type generally has higher survival rates, with of patients surviving after being discharged from the hospital.
However, of patients die within years post-discharge. These deaths are often associated with a history of aortic aneurysm, atherosclerosis, or pleural effusion.
Higher mortality risks are correlated with older age and existing medical comorbidities.
Reduction of Complications: Long-term complications can be mitigated through the strict control of blood pressure and regular aortic imaging.
Role of Respiratory Therapists in Management
Context: Because patients with aortic dissection often experience acute lung injury and oxygenation impairment, Respiratory Therapists (RTs) are essential in management.
Airway Management: RTs assist with intubation and the management of mechanical ventilation for critically ill patients, particularly those facing respiratory failure or undergoing surgery.
Oxygen Therapy: RTs administer and adjust supplemental oxygen levels to ensure tissues and organs remain adequately oxygenated, which is vital given the patient's impaired circulation.
Postoperative Care:
RTs aid in the process of weaning patients off mechanical ventilation following surgical procedures.
They implement and teach specific techniques to promote lung expansion and secretion clearance.
Specific techniques include breathing exercises, chest physiotherapy, and the use of incentive spirometry to reduce the likelihood of postoperative pulmonary complications.
Overview and Definition of Arteriovenous Malformation
Arteriovenous Malformation (AVM) is a medical condition characterized by the abnormal formation of blood vessels in a specific part of the body.
In a healthy circulatory system, blood follows a specific progression: arteries arterioles capillary bed venules veins.
In an AVM, this progression is disrupted. There is a direct connection between arteries and veins, effectively bypassing the capillary bed.
Signs and Symptoms
Symptoms of AVMs vary significantly depending on the location of the malformation within the body.
Brain AVM Symptoms
Frequent migraines.
Seizures of any kind.
A bruit (a sound of blood rushing) that can be heard by the individual with the AVM.
Vision issues.
Loss of the sense of taste or smell.
Confusion and memory loss.
Intracerebral hemorrhage, which carries the risk of leading to a stroke.
Spinal Cord AVM Symptoms
Sudden and severe back pain.
Localized paralysis affecting the extremities.
Stiffness in the legs or arms.
Unusual or unexplained bodily pain.
Loss of control over bladder or bowel functions.
Symptoms in Other Body Regions
Integumentary Symptoms: If the AVM is on the skin, it may cause swelling, pain, weakness, immobilization, redness, or bruising in the affected area.
Bone Symptoms: If the AVM is located on or near a bone, it can lead to the erosion of bone tissue.
Pulmonary Symptoms: AVMs in the lungs can cause dyspnea (shortness of breath), lethargy, and hemoptysis (coughing up blood).
Gastrointestinal Symptoms: Malformations in the stomach or intestines can cause internal bleeding, hematemesis (vomiting blood), and melena (dark, tarry stools).
Clinical History and Assessment
When evaluating a patient for a suspected AVM, several critical questions must be addressed during the history-taking process:
Has the patient experienced a sudden onset of pain in the head, back, or extremities?
Is there any evidence of numbness, tingling, weakness, stiffness, or paralysis in the extremities?
has the patient experienced unexplained dizziness, shortness of breath, coughing up blood, or recent unexplained cramping?
If symptoms are present, when did they first appear and what is their frequency?
Does the patient have a personal or family history of Parkes-Weber syndrome or Hereditary Hemorrhagic Telangiectasia?
Etiology and Risk Factors
The exact causes of Arteriovenous Malformations are currently unknown.
Some cases are attributed to genetic changes occurring early in utero; however, these specific mutations are not typically inherited.
AVMs can occur as a symptom of specific hereditary syndromes, including:
Parkes-Weber syndrome.
Hereditary Hemorrhagic Telangiectasia.
Physical Examination Findings
External signs of an AVM are rare unless the malformation affects the superior layers of the integument (skin).
Patients often present with a sudden onset of pain that is frequent and localized to the site of the AVM.
If an AVM ruptures and the resulting bleed is neither contained nor controlled, the patient will exhibit symptoms of a hemorrhagic stroke.
Seizures may be present and otherwise unexplained.
Pathophysiology
The primary physiological issue in an AVM is increased blood flow caused by the bypassing of the capillary network.
Arteries are naturally thick-walled and built for high-pressure environments, whereas veins are thin-walled and designed for low pressure.
Because the AVM connects these directly, the entangled veins can become distended and weak.
Rupture Risks: If these weakened veins rupture in the brain, an intracerebral hemorrhage occurs. While surrounding brain tissue may apply pressure to help stop the bleed, an untreated AVM remains at risk for repeated ruptures. Subsequent, worse bleeding can lead to a hemorrhagic stroke.
Spinal Impact: If a rupture occurs in the spinal cord, it can result in hemiplegia (paralysis of one side of the body), hemiparesis (weakness on one side of the body), and severe pain.
While hemorrhagic strokes resulting from AVMs are considered rare, they often have severe or fatal outcomes.
Investigations and Diagnosis
Comprehensive diagnosis relies on an in-depth history and a physical examination of the affected area, followed by diagnostic imaging:
Ultrasound: Frequently utilized to visualize blood vessels in the immediate vicinity of the AVM.
MRI (Magnetic Resonance Imaging): Provides a highly detailed picture of the AVM's precise location and can visualize the nerves surrounding the affected area.
CT-Scan: Used to determine if the AVM is impacting other structures, such as bone.
Angiogram: Reserved for extreme cases with severe symptoms. This procedure involves "mapping" the blood vessels to provide a highly detailed picture. It is performed under anesthesia.
Management and Treatment
There is currently no specific medication designed to cure AVMs. Treatment focuses on symptom management and surgical intervention.
Symptomatic Relief
Administration of anti-seizure medications.
Use of analgesia for pain management.
Surgical Options
Microsurgical Resection: The physical removal of the AVM, typically performed if the lesion is in an accessible area of the body.
Endovascular Embolization: A procedure where a tiny wire is placed into the artery to deliver various agents that plug the AVM opening on the arterial side. This slows or stops the blood flow through the malformation.
Radiosurgery: The application of a high dose of focused radiation to the AVM, which causes the vessels in the lesion to eventually close.
Conservative Management
If the risks of surgery outweigh the potential benefits, a strategy of observation may be adopted to monitor the AVM for complications.
Complications1. Hemorrhage
Rupture can cause an intracerebral hemorrhage (ICH) or a subarachnoid hemorrhage (SAH), which is bleeding between the brain and the skull.
Small AVMs, defined as those measuring less than , are statistically more likely to burst than larger ones.
These bleeding events can lead to a stroke.
2. Physical Displacement and Pressure
AVMs can increase in size, exerting pressure on the surrounding brain tissue. This is more common with large AVMs.
This pressure can lead to seizures and hydrocephalus, which is the accumulation of excessive cerebrospinal fluid in the brain.
3. Tissue Hypoxia and Necrosis
AVMs can reduce the delivery of oxygen to nearby brain tissue.
The high pressure inside the AVM creates a "vacuum effect," which deprives nearby tissues of blood flow.
This can lead to tissue hypoxia and subsequent necrosis.
4. Pediatric Considerations
In rare instances, AVMs can cause heart failure in infants and children due to the high blood flow through the malformation combined with the smaller total volume of blood in their systems.
AVMs are also associated with developmental delays in children.
Epidemiology and Statistics
AVMs affect approximately of the population in North America.
Many individuals with an AVM are unaware of the condition because they experience mild or no symptoms.
Fewer than of AVMs result in a hemorrhagic stroke.
Overview of Cerebrovascular Accident (CVA)
A cerebrovascular accident, commonly referred to as a stroke, is a clinical event that occurs when blood flow to a specific part of the brain is lost, resulting in tissue damage.
Stroke occurs when blood flow is impaired either by a blockage or the rupture of an artery, leading to the death of brain cells from a lack of oxygen.
Signs and Symptoms
Dizziness.
Numbness.
Weakness localized to one side of the body.
Cognitive and communicative problems, including difficulties with talking, writing, or understanding.
Sudden difficulty with walking and physical coordination.
Sudden trouble with vision in one or both eyes.
A sudden headache with no known cause, which is a symptom more commonly associated with hemorrhagic strokes.
Clinical History and Patient Intake
When establishing a patient history, the following specific questions should be addressed:
What specific symptoms were experienced (e.g., weakness, numbness, or difficulty breathing)?
Is there a history of previous strokes or transient ischemic attacks (TIAs)?
Is there a medical history of hypertension, heart disease, or heart failure?
Does the patient smoke or drink alcohol? If so, documentation must include how much and how often.
What medications are currently being taken, including over-the-counter supplements?
Is the patient currently taking blood thinners or anti-platelet agents?
Etiology and Risk Factors
Hypertension (high blood pressure).
Diabetes.
Heart disease.
High cholesterol.
Atrial fibrillation.
History of previous stroke or transient ischemic attack (TIA).
Smoking.
Obesity.
Pathophysiology of Stroke Types
Ischemic Stroke
This is the most common type of stroke, accounting for of all cases.
It is caused by a blockage in a vessel that supplies blood to the brain.
Thrombosis: The formation of a blood clot within a blood vessel located in the brain.
Embolism: A blood clot from another part of the body that travels to the brain and blocks a blood vessel.
Atherosclerosis: The buildup of plaque within the arteries, leading to the narrowing and potential blockage of those arteries.
Hemorrhagic Stroke
This type is caused by bleeding occurring either in or around the brain.
Aneurysms: Bulging, weak areas in the walls of arteries that have the potential to burst.
Hypertension: Chronic high blood pressure can weaken blood vessels over time, eventually causing them to rupture.
Arteriovenous Malformations (AVMs): Abnormally tangled vessels that are prone to rupturing.
Subcategories include intracerebral or subarachnoid hemorrhages.
Investigations and Diagnosis
FAST Method for Identification
Face: Ask the patient "Can you smile?" and observe if one side of the face droops.
Arms: Ask the patient "Can you raise both arms?" and observe if one arm drifts downward.
Speech: Ask the patient to repeat a simple phrase (e.g., "The grass is green") to check if they can repeat it correctly or if their words are slurred.
Time: Determine when the symptoms started. If any of the above symptoms are present, emergency help must be sought immediately.
Diagnostic Testing
Neuroimaging: Computed Tomography (CT) scans or Magnetic Resonance Imaging (MRI) are used to distinguish between ischemic and hemorrhagic strokes and determine the location of the damage.
Cardiac Testing: Electrocardiogram (ECG or EKG) is utilized to detect atrial fibrillation or other underlying heart conditions.
Blood Tests: These are conducted to identify risk factors such as high cholesterol.
Management and Treatment
Rapid assessment is performed using the FAST assessment test.
Type and location are confirmed via neuroimaging (CT and MRI).
Thrombolytic Therapy for Ischemic Strokes:
Administration of tissue plasminogen activator (tPA) to dissolve blood clots and restore blood flow.
Medical intervention with tPA must occur within of the onset of symptoms.
Interventions for Hemorrhagic Strokes:
Surgical procedures such as coiling aneurysms.
Procedural removal of large hematomas.
Blood Pressure Management: Utilizing medication to control and manage hypertension.
Lifestyle Modifications: Implementing a healthy diet, engaging in regular physical activity, and eliminating tobacco use to manage cardiovascular health.
Complications
Ischemic Stroke Complications:
Permanent weakness, numbness, or garbled speech.
Seizures.
Memory problems.
Hemorrhagic Stroke Complications:
Seizures.
Memory and thinking problems.
Heart-related problems.
Swallowing difficulties and trouble eating or drinking.
Permanent neurologic disability.
Definition and Clinical Overview
Intraventricular Hemorrhage (IVH) is a specific type of brain bleed defined by bleeding into the ventricles, which are the fluid-filled cavities located within the brain.
The presence of blood within these spaces can exert physical pressure on surrounding nerve cells, leads to damage, and may result in permanent brain injuries.
Clinical Manifestations (Signs and Symptoms)
In many clinical cases, Intraventricular Hemorrhage is asymptomatic, meaning it presents with no observable symptoms.
When symptoms do occur, the most common clinical signs include:
Breathing pauses, medically referred to as apnea.
Low heart rate (bradycardia).
Decreased muscle tone (hypotonia).
Decreased reflexes.
Cyanosis (a bluish discoloration of the skin resulting from poor circulation or inadequate oxygenation of the blood).
Lethargy.
Weak suck reflex in the infant.
Neonatal seizures.
Bulging fontanelle, which is the swelling of the infant's soft spot due to increased intracranial pressure.
Medical History and Risk Assessment
High-risk profiles for infants include:
Mothers who are at high risk of delivering early.
Mothers with a clinical history of previous premature births.
Infant status at birth often involves:
Premature birth status.
Experience of a traumatic birth.
Clinical signs of infection.
Etiology and Risk Factors
Several factors increase the likelihood of an infant developing IVH:
Acute inflammation of the placenta during pregnancy.
An increased number of leukocytes (white blood cells) detected within the first following birth.
A generally elevated white blood cell count.
Hypercapnia (an abnormally high level of carbon dioxide in the blood).
The onset of early sepsis (a severe systemic infection).
Low birth weight.
An Apgar score of or lower at the mark after birth.
Grading and Classification of Bleeds
Intraventricular Hemorrhage is categorized into four distinct grades based on the extent and location of the bleeding. Any of these grades can occur unilaterally (on one side) or bilaterally (on both sides).
Grade 1: The hemorrhage occurs specifically at the level of the germinal matrix and does not extend into the ventricles.
Grade 2: Blood from the germinal matrix area enters the ventricles. In this grade, the blood fills less than of the ventricular volume, and there is no observable dilation (widening) of the ventricles.
Grade 3: This is an extension of Grade 2 where blood enters at least of the ventricles. Crucially, this volume of blood causes the ventricles to dilate.
Grade 4: A severe insult where blood enters the cerebral cortex (brain matter). This grade does not necessarily involve blood in the ventricles initially, but the volume of blood in a Grade 3 bleed can lead to an infarct (tissue death due to lack of blood supply) in the area of the cerebrum.
Pathophysiology
The primary causes of Intraventricular Hemorrhages are believed to be destabilizing changes in cerebral blood flow and intracranial pressure, alongside the loss of cerebral autoregulation.
To mitigate these risks, many Neonatal Intensive Care Units (NICUs) maintain a midline head position for premature infants, as this positioning is thought to stabilize blood flow and pressure.
Investigations, Diagnosis, and Post-Hemorrhagic Complications
Clinical concern often focuses on the secondary effects of the bleed rather than the bleed itself, specifically whether the bleed resolves spontaneously or leads to further complications.
Post-haemorrhagic hydrocephalus: This occurs when the blood from a Grade 2 or Grade 3 bleed is not reabsorbed. Instead, the blood clogs the ventricular system, preventing Cerebrospinal Fluid (CSF) from draining. As the CSF builds up, it results in hydrocephalus.
Arachnoid Villi Involvement: Blood may settle over the arachnoid villi, which are responsible for absorbing CSF. If these villi are obstructed by blood, they cannot function properly, leading to CSF accumulation in the ventricles.
Physical Indicators: The build-up of CSF causes the ventricles and the skull to push outward. The head circumference will grow much faster than the normal rate of to .
Statistics:
of infants with Grade 3 or Grade 4 bleeds will develop post-haemorrhagic hydrocephalus.
of those who develop hydrocephalus will require a permanent drainage system to manage intracranial pressure.
Hydrocephalus associated with IVH is typically classified as obstructive hydrocephalus.
Management, Prevention, and Treatment
Treatment: Currently, there is unfortunately no direct treatment for Intraventricular Hemorrhage itself.
Prevention Strategies:
Pregnant women identified as high-risk for early delivery may be administered corticosteroids to help reduce the infant's risk of developing IVH.
NICUs often practice maintaining a midline head position for the first of life. While more studies are needed, this practice aims to reduce IVH by decreasing fluctuations in cerebral blood flow.
Surgical Interventions for Hydrocephalus:
To relieve pressure, a neurosurgeon may place a ventricular reservoir that is routinely tapped once per day () or every two days ().
As the infant grows older, the reservoir may be replaced with a ventriculoperitoneal (VP) shunt. This tubing runs from the ventricles to the peritoneal cavity, which is more effective at absorbing the excess fluid.
Clinical Monitoring: Infants must undergo regular brain scans and frequent head circumference measurements to monitor for fluid buildup.
Prognosis: The prognosis for an infant with a Grade 3 bleed that resolves naturally is significantly better than for an infant with Grade 3 IVH who progresses to post-haemorrhagic hydrocephalus and requires a shunt. Surgical management, as noted by Dr. Chang, can be very difficult.
Overview and Pathophysiology of Pulmonary Embolism
Pulmonary embolism is a condition caused by a blood clot, or multiple clots, that obstruct the flow of blood to one or both of the lungs.
The most frequent cause is a deep vein thrombosis (). This thrombosis typically originates in a vein located within the leg.
The pathological process begins when a piece of the breaks off from the vessel wall and travels through the circulatory system to the lungs. This results in the interruption of blood flow.
This interruption may cause the affected section of the lung tissue to die (infarction), which consequently impacts the oxygenation levels throughout the entire body.
The extent of the damage is contingent upon the size of the embolus involved:
Small emboli are associated with the development of ventilation-perfusion mismatch and hypoxemia.
Large pulmonary emboli can lead to a full pulmonary infarction and the total occlusion of pulmonary vessels.
When vessels become obstructed, it can lead to subsequent vasoconstriction within the pulmonary arteries.
Clinical Presentation and Patient History
Signs and symptoms that may indicate a pulmonary embolism include:
Chest pain.
Dyspnea (shortness of breath).
Tachypnea (abnormally rapid breathing).
Tachycardia (abnormally rapid heart rate).
Sudden and unexplained anxiety.
Fainting (syncope).
Hemoptysis (coughing up blood).
When taking a patient history, specific questions must be asked regarding:
A previous history of blood clots.
Recent experiences of long periods of inactivity, such as lengthy travel or bed rest.
Etiology and Risk Factors
Several risk factors contribute to the development of pulmonary embolisms, including:
Use of birth control medications.
Hormone replacement therapy.
Obesity.
Smoking.
Pre-existing heart disease.
Pregnancy.
Diagnostic Investigations and Exam Findings
D-dimer blood test: This test measures D-dimer levels, which rise specifically when a blood clot begins to break apart.
CT scan: Used to visualize the clot directly. Findings may include a white ring or a clear indication of blocked blood flow.
Doppler ultrasound: Utilized to visualize a blood clot or pulmonary embolism, often in the context of checking for .
Echocardiogram: Provides visualization of the heart; abnormalities found in the Right Ventricle () can serve as an indicator of a pulmonary embolism.
Ventilation/Perfusion () scan: This test is performed to determine if there is abnormal or restricted blood flow to the lungs.
Chest X-ray: While not definitive for PE, it is used as a differential diagnostic tool to rule out other conditions such as pneumonia or an enlarged heart.
Management, Treatment, and Complications
Pharmacological interventions include:
Anticoagulants to prevent further clotting.
Thrombolytic therapy to dissolve existing clots.
For patients suffering from recurrent clots, a surgical procedure may be required. This involves placing a specialized filter into the vena cava.
Compression socks are utilized as a supportive and preventative management tool.
Potential complications of pulmonary embolism include:
The exacerbation of pre-existing heart or lung conditions.
Cardiac arrest.
Pleural effusion.
Overview of Myocardial Infarction
A Myocardial Infarction (MI) is a clinical event that occurs when there is a significant decrease or a complete cessation of blood flow through the coronary arteries to a specific portion of the myocardium.
This disruption in blood flow leads to ischemia and potential necrosis of the heart muscle tissue.
Signs and Symptoms
Chest pain, also referred to as angina, is a primary indicator.
Pain commonly radiates or spreads to other areas of the body, including:
The arms.
The neck.
The jaw.
The back.
Shortness of breath, clinically known as dyspnea.
Feelings of dizziness or disorientation.
Heart palpitations, characterized by the sensation of a racing, fluttering, or pounding heart.
Gender-specific presentations in females:
Occurrence of cold sweats.
Pain may be misinterpreted as heartburn or indigestion.
Clinical History and Assessment Questions
Determining the presence of a familial predisposition: Has a close relative had Coronary Artery Disease (CAD) or a previous Myocardial Infarction?
Assessment of current symptomatic state: Are you currently experiencing chest pain?
Lifestyle and behavioral factors: Do you smoke?
Pre-existing cardiovascular conditions: Do you have high blood pressure?
Pharmacological history: Do you take any heart medications?
Etiology and Risk Factors
The primary cause of Myocardial Infarction is Coronary Artery Disease (CAD).
Major risk factors contributing to the development of an MI include:
Hypertension (HPN).
Smoking tobacco products.
Obesity, lack of physical exercise, and a poor diet.
Diabetes mellitus.
High cholesterol levels, specifically characterized by a poor ratio of to .
Gender: Males are at higher risk earlier in life.
Advanced age.
Genetics: Risk increases significantly if a close relative has experienced a Myocardial Infarction.
Clinical Examination Findings
Patients typically present with active chest pain upon admission to a clinical setting.
Electrocardiogram (ECG) changes are crucial for identification, including:
-segment elevation.
-segment depression.
A likely underlying diagnosis or history of Coronary Artery Disease is frequently observed.
Pathophysiology of Myocardial Infarction
The fundamental cause of an MI is a lack of oxygen supplied to the heart muscle cells, known as cardiomyocytes.
The oxygen deficit may result from two primary mechanisms:
The restriction of oxygenated blood flow to the heart tissue.
The metabolic demand for oxygen by the cardiomyocytes exceeds the total amount of oxygen available for effective functioning.
As cardiomyocytes become deprived of oxygen, they send pain signals to the brain.
In response to low oxygen levels, the brain releases adrenaline as a compensatory mechanism.
If the required amount of oxygen is not restored to the cardiomyocytes, the cells begin to accumulate toxins and eventually rupture.
Following cellular rupture, there is permanent physiological damage to the cardiomyocytes, preventing them from functioning as they did previously.
Investigations and Diagnostic Criteria
Diagnosis is established through three primary avenues:
Clinical Features: Assessment of chest pain, dyspnea, fatigue, and a documented history of CAD or multiple known risk factors.
ECG Findings: The presence of -segment elevation or depression indicates active arterial occlusion. Other specific changes on the ECG can provide evidence of a past Myocardial Infarction.
Serum Troponins: Elevation of cardiac-specific proteins, specifically and . A diagnostic value of > 14\,ng\,dm^{-3} is used to identify myocardial injury.
Management and Treatment Interventions
Pharmacological Therapy:
Aspirin: Administered as a blood thinner to improve blood flow through the vessels.
Nitroglycerin: Acts to widen blood vessels (vasodilation) to increase the volume of blood flow.
Beta-blockers: Utilized to decrease the heart rate, thereby reducing cardiac workload.
Surgical and Procedural Interventions:
Percutaneous Coronary Intervention (PCI): The placement of a stent at the site of the blockage to mechanically keep the artery open.
Coronary Artery Bypass Grafting (CABG): A form of open-heart surgery, also known as bypass surgery, to reroute blood flow around obstructed arteries.
Oxygen Therapy: Employed to increase oxygen circulation throughout the body and alleviate pressure on the heart muscle.
Potential Complications and Sequelae
Permanent damage to the heart muscle cells.
Alterations in the heart's rhythm; the heart may no longer beat with the same regularity or efficiency.
Increased susceptibility to other cardiovascular diseases.
Development of respiratory disorders.
Stroke.
Heart failure.
Death.
Roles of the Respiratory Therapist (RT)
Administration of oxygen therapy to reduce the overall workload on the patient's heart.
Provision of ventilatory support to decrease the patient's work of breathing ().
Monitoring and checking Arterial Blood Gases () to assess oxygenation and acid-base balance.
Regularly checking vital signs and performing comprehensive physical assessments.
Definition and Significance of Stroke
A stroke, also known as a Cerebrovascular Accident (CVA), is defined as a sudden interruption of blood flow to the brain, spinal cord, or retina. This interruption results in brain tissue infarction (tissue death due to lack of blood supply) or hemorrhage (bleeding).
Brain cells strictly require a continuous and uninterrupted supply of oxygen and glucose to function. When blood flow is interrupted, neuronal injury begins to occur within minutes.
Stroke is classified as a medical emergency. Rapid clinical intervention and treatment significantly improve patient outcomes.
Classification of Stroke
Ischemic Stroke ():
This type occurs when a blood vessel supplying the brain becomes obstructed.
Transient Ischemic Attack (TIA): Characterized by a temporary interruption of blood flow that does not cause permanent brain damage; it is considered a critical warning sign for potential future strokes.
Thrombotic Stroke: Occurs when a clot forms specifically within a cerebral artery that has been narrowed by atherosclerosis.
Embolic Stroke: Occurs when a clot forms elsewhere in the body—most commonly in the heart during atrial fibrillation—and subsequently travels through the bloodstream to the brain where it lodge in a vessel.
Hemorrhagic Stroke ():
This type occurs when a cerebral blood vessel ruptures, leading to bleeding either into the brain tissue itself or the space surrounding the brain.
Common etiologies include hypertension (high blood pressure), aneurysms, and arteriovenous malformations.
Risk Factors and Prevention strategies
Non-modifiable Risk Factors:
Increasing age.
Biological sex.
Family history and genetics.
History of previous stroke or Transient Ischemic Attack (TIA).
Race and ethnicity.
Modifiable Risk Factors:
Hypertension.
Atrial fibrillation.
Diabetes.
Dyslipidemia.
Smoking.
Obesity.
Physical inactivity.
Prevention and Management Strategies:
Strict blood pressure control.
Statin therapy where clinically indicated.
Management of diabetes.
Anticoagulation therapy specifically for those with atrial fibrillation.
Smoking cessation.
Adherence to a healthy diet and regular exercise.
Prompt and aggressive treatment of TIAs.
Pathophysiology of Stroke
Thrombotic Stroke Mechanism:
Rupture of atherosclerotic plaque leads to platelet activation.
This triggers the formation of a fibrin clot, resulting in arterial occlusion.
Occlusion cause decreased cerebral blood flow, leading to ATP depletion.
The final stages involve neuronal infarction and definitive cell death.
Embolic Stroke Mechanism:
A clot forms in a distal location (usually the heart) and travels to the brain.
The clot blocks a cerebral artery, causing reduced cerebral perfusion.
This triggers the ischemic cascade, characterized by ATP depletion, calcium influx, inflammation, and oxidative stress.
If left untreated, the process results in irreversible neuronal injury.
Hemorrhagic Stroke Mechanism:
A blood vessel rupture leads to bleeding into the brain tissue.
This causes increased intracranial pressure (ICP) and the compression of surrounding brain tissue.
Compression leads to decreased cerebral perfusion, resulting in ischemia and neuronal death.
Additionally, blood products trigger inflammation and cerebral edema, which further exacerbate the injury.
Clinical Manifestations and the BE-FAST Tool
General Symptoms:
Sudden unilateral weakness or numbness (affecting one side of the body).
Facial droop.
Speech difficulty, including aphasia (loss of ability to understand or express speech) or dysarthria (difficult or unclear speech).
Vision changes.
Loss of balance or coordination.
Altered state of consciousness.
Severe headache, which is particularly characteristic of hemorrhagic stroke.
BE-FAST Assessment Tool:
B: Balance loss.
E: Eyes (vision changes).
F: Face drooping.
A: Arm weakness.
S: Speech difficulty.
T: Time to call emergency services.
Diagnosis and Time-Sensitive Goals
Key Diagnostic Tools:
Non-contrast Computed Tomography (CT).
Magnetic Resonance Imaging (MRI).
CT angiography.
NIH Stroke Scale (NIHSS) for clinical severity.
Blood glucose monitoring and coagulation studies.
Clinical Time Goals:
CT scan should be performed within approximately .
Intravenous (IV) thrombolysis should be administered within .
Mechanical thrombectomy may be performed up to in specifically selected patients.
Management of Stroke
Ischemic Stroke Management:
Administration of Alteplase (tPA) or Tenecteplase (TNK).
Mechanical thrombectomy for clot removal.
Management of blood pressure.
Antiplatelet therapy.
Anticoagulation for cardioembolic strokes when appropriate.
Hemorrhagic Stroke Management:
Rapid and aggressive blood pressure control.
Reversal of any existing anticoagulation.
Management of intracranial pressure (ICP).
Neurosurgical intervention, such as clipping or coiling of an aneurysm, when indicated.
Supportive care within a specialized stroke unit.
Respiratory Therapist (RT) Responsibilities
Maintaining the patient's airway and ensuring adequate oxygenation.
Avoiding the extremes of hypoxemia (low oxygen) and hyperoxia (excess oxygen).
Ventilator management with the specific goal of maintaining normoxia and normocapnia (normal carbon dioxide levels).
Continuous monitoring of Arterial Blood Gases (ABGs), Oxygen Saturation (), and End-Tidal Carbon Dioxide ().
Implementing measures to prevent aspiration.
Airway clearance and secretion management including suctioning when necessary.
Assisting with the rehabilitation process and the weaning of patients from mechanical ventilation.
Providing essential education to patients and their caregivers.
Engaging in interprofessional collaboration with nursing staff, physicians, and speech-language pathologists.
Prognosis and Functional Outcomes
Factors Influencing Recovery:
Total time elapsed before treatment.
Initial stroke severity.
The specific type of stroke (Ischemic vs. Hemorrhagic).
The location and size of the brain lesion.
Individual patient age.
Presence of comorbidities.
Access to early rehabilitation.
Strength of social support systems.
Effectiveness of secondary prevention and control of risk factors.
Functional outcomes and levels of disability are commonly measured using the Modified Rankin Scale (mRS).
Overview and Definition of Myasthenia Gravis
Myasthenia Gravis is an autoimmune disorder characterized by impaired transmission of neural impulses across the neuromuscular junction.
The primary mechanism of the disorder is the destruction of the postsynaptic receptors.
Signs and Symptoms
Muscle fatigue is a hallmark of the condition and is typically more severe in the afternoon.
Muscle involvement often follows a specific progression, affecting the ocular, facial, and bulbar muscles first.
Limb or respiratory muscle weakness may occur.
Ptosis, which is the drooping of the eyelids, is a common symptom.
Drooling and an inability to chew or swallow are also observed.
Risk Factors and Etiology
There is no known cause for Myasthenia Gravis, which means there are no certain risk factors.
Gender and Age Considerations:
Women are affected more frequently than men, particularly those under the age of .
The common age of onset for women is between and years old.
The common age of onset for men is typically greater than years old.
Thymus Abnormalities: These are frequently associated with the condition, especially in cases involving hyperplasia or a thymoma.
Genetics: A personal or family history of autoimmune disease is considered a potential risk factor.
Triggers: Stress, infections, and certain medications may trigger the condition in some individuals.
Etiology Specifics:
The cause is technically unknown, though thymus abnormalities are suspected to play a significant role.
In Transient Neonatal MG, the etiology is the passage of antibodies from the mother to the baby.
Pathophysiology of the Neuromuscular Junction
The body generates auto-antibodies against Acetylcholine () receptors, , and protein.
and proteins are specifically involved in clustering at the neuromuscular junction.
Antibodies disrupt neuromuscular transmission through three primary mechanisms:
Blocking (Acetylcholine receptors), which inhibits binding for the propagation of action potentials.
Activating the complement system at the neuromuscular junction, which causes local damage to the junction itself.
Blocking the binding sites and functions of and , thereby inhibiting their ability to stabilize at the junction.
Clinical Examination Findings
Rapid muscular fatigue and weakness are evident during examination.
Ptosis and various vision problems are frequently noted.
Patients often experience difficulty making facial expressions.
Difficulties with swallowing and speaking (bulbar symptoms) are clinically significant finding.
Investigations and Diagnostic Tools
Physical Exam: The initial step in assessment.
Antibody Testing: Used for definitive diagnosis by checking for auto-antibodies including , , and .
If a patient is positive, follow-up imaging of the thymus via CT, MRI, or PET scan is required.
Electrodiagnostics:
Repeated Nerve Stimulation.
Neuromuscular Jitter Fiber-Single Fiber Electromyopathy is employed to evaluate the efficiency of neurotransmission and action potentials.
Pharmacological Testing: The Tensilon test uses Esterase to evaluate for the reversal of muscle weakness.
Management and Treatment Interventions
Anticholinesterases: These medications work by increasing the availability of at the neuromuscular junction.
Glucocorticosteroids: These are used to suppress the immune system's production of auto-antibodies.
Immunosuppressants: These aim to reduce the overall generation of auto-antibodies.
Targeted Therapies: These medications competitively bind with auto-antibodies.
Plasmapheresis: A process of filtering the blood to physically remove auto-antibodies.
Thymectomy: The surgical removal of thymic tumors (if they are present) to reduce the generation of auto-antibodies.
Respiratory Support: In cases where breathing becomes impaired, management must move toward intubation and mechanical ventilation.
Complications: Myasthenic and Cholinergic Crises
Myasthenic Crisis:
This is an exacerbation of Myasthenia Gravis caused by infection, missed medication, stress, trauma, or idiopathic reasons.
It results in severe quadriparesis or quadriplegia.
It includes the loss of movement in respiratory muscles.
Patients are at a high risk for aspiration and respiratory failure.
Cholinergic Crisis:
This is a response to anticholinesterase medication that results in an extreme parasympathetic response.
Symptoms include bradycardia, bradypnea, and diaphoresis.
Extreme GI issues such as cramping and diarrhea are characteristic.
disease Classifications and Antibody Subtypes
Disease Classifications:
Ocular: This form affects only the eyes and eyelids, representing roughly of cases.
Generalized: This can affect the eyes, face, neck, limbs, and respiratory muscles, representing roughly to of cases.
Transient Neonatal MG: This occurs when autoantibodies cross from the mother to the baby; it is only a temporary condition.
Juvenile MG: Diagnosis occurs when symptoms onset before the age of years.
Antibody Subtypes:
antibody-positive MG: This is the most common subtype.
antibody-positive MG.
antibody-positive MG.
Triple-seronegative MG: A classification used when there are no detectable auto-antibodies.
Prevention and Symptom Mitigation
There is no known way to prevent the development of the disease because there is no known cause.
Strategies to prevent the worsening of symptoms include:
Resting and avoiding strenuous physical activity.
Avoiding exposure to extreme temperatures.
Avoiding emotional stress.
Avoiding exposure to illnesses.
Staying up to date with vaccinations.
Maintaining effective treatment plans.
Avoiding specific medications known to worsen symptoms.
Overview of Muscular Dystrophy
Muscular dystrophy (MD) refers to a group of genetic disorders characterized by progressive muscle weakness and degeneration.
The condition occurs due to mutations in genes responsible for producing proteins that help protect muscle fibers.
Over time, these genetic mutations cause the muscles to weaken and undergo significant deterioration.
Specific Types of Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD): This is the most common type and usually affects boys. It typically begins in early childhood and leads to progressive difficulty with walking.
Becker Muscular Dystrophy (BMD): This type is similar to Duchenne Muscular Dystrophy but is generally characterized by a less severe progression.
Myotonic Dystrophy: This form affects adults and causes muscles to remain in a state of contraction (stay tight) after use.
Facioscapulohumeral Muscular Dystrophy (FSHD): This type primarily affects the muscles within the face, shoulders, and arms.
Limb-Girdle Muscular Dystrophy: This variety specifically targets the muscles located around the hips and the shoulders.
Risk Factors and Etiology
Risk Factors:
Family History: Individuals with a family member who has MD have an increased likelihood of developing the condition.
Genetic Mutations: Specific changes in certain genes are the direct cause of MD.
Gender: Certain types of the disorder, specifically Duchenne and Becker muscular dystrophies, occur almost exclusively in boys.
Ethnicity and Geography: The prevalence of certain types of MD may be higher within specific ethnic groups or geographical areas.
Parental Age: There is a slightly higher chance of a child having new genetic mutations that could cause MD if the parents are older.
Etiology (Causes):
MD is caused by changes in genes that are essential for maintaining muscle health. These changes can occur in two ways:
Inherited: Genetic changes are passed down from parents to their children.
Spontaneous: Changes in genes happen even without a family history of the disease.
Clinical Manifestations and Presentation
Common Signs and Symptoms:
Frequent falls
Waddling gait
Walking on the toes or the balls of the feet
Delayed motor milestones
Gower’s sign (a medical sign where a patient has to use their hands and arms to "walk" up their own body from a squatting position due to lack of hip and thigh muscle strength)
Muscle atrophy (wasting of muscle tissue)
Limited joint mobility
Difficulty closing the eyes
Difficulty smiling or being expressive
Speech impediments
Less Common Signs and Symptoms:
Fatigue
Pseudohypertrophy (false enlargement of muscles, often the calves, due to fat and connective tissue replacement)
Shortness of breath
Abnormal heart rhythm
Peripheral edema (swelling in the lower limbs)
Poor appetite
Wheezing
Ptosis (drooping of the upper eyelid)
Difficulty swallowing
Diagnostic Tools
Primary Diagnostic Tools:
Physical examination, which includes checking for Gower’s sign.
Walk tests to assess mobility.
Spinal curvature assessment.
Creatine Kinase (CK) blood test (elevated levels indicate muscle damage).
Genetic testing to identify specific mutations.
Secondary Diagnostic Tools:
Muscle biopsy (removing a small sample of muscle for laboratory analysis).
Electromyography (EMG) to measure the electrical activity of muscles.
Diagnostic imaging, such as Magnetic Resonance Imaging (MRI) or ultrasounds.
Heart function tests to monitor cardiac involvement.
Pathophysiology
Genetic mutations result in the production of abnormal dystrophin, which is the primary protein responsible for maintaining muscle function.
This abnormality leads to a physical weakening of the sarcolemma, the cell membrane that surrounds a muscle fiber.
The weakened sarcolemma leads to a cascade of cellular damage, including:
Muscle tearing.
Increased muscle fragility.
Calcium dysregulation within the muscle cells.
Muscle wasting.
As this cycle repeats continuously, the muscle cells eventually die, a process known as necrosis.
The dead muscle tissue is replaced by scar tissue and fat tissue.
Management and Treatment Strategies
Medical Treatments:
Corticosteroids to slow muscle degeneration.
Gene therapy to address the underlying genetic causes.
Exon skipping, a strategy used to bypass certain mutations in the gene.
Cardiac medications to manage heart-related complications.
Pacemaker insertion for heart rhythm regulation.
Braces and mobility aids to assist with movement.
Therapeutic Interventions:
Physical therapy to maintain strength and flexibility.
Occupational therapy to assist with daily living activities.
Speech therapy to address communication or swallowing difficulties.
Mental health therapy to support emotional well-being.
Respiratory therapy to manage pulmonary complications.
Prognosis and Outcomes
The prognosis for individuals with muscular dystrophy is entirely dependent on the specific type, subtype, and the rate at which the disease progresses.
For patients with Duchenne Muscular Dystrophy (DMD), survival typically extends into the or .
Survivability decreases significantly once the respiratory and cardiac systems become involved.
Prompt diagnosis and the early initiation of treatment are critical factors for achieving the best possible quality of life and improving survivability.
Respiratory Therapy Role and Management
Maintaining pulmonary function is an essential priority for patients with MD.
Patients are highly susceptible to developing an ineffective cough and decreased ventilation.
Potential Complications:
Respiratory muscle fatigue.
Mucus plugging.
Pneumonia.
Atelectasis (collapse of lung tissue).
RT Equipment and Skills:
Cough assist devices.
Pulmonary function tests (PFTs).
Positive Expiratory Pressure (PEP) and Oscillating Positive Expiratory Pressure (OPEP) therapy.
Bilevel Positive Airway Pressure (BiPAP).
Tracheostomy management.
Oxygen administration.
Suctioning techniques.
Use of humidifiers.